US5994041A
(en)
*
|
1985-04-06 |
1999-11-30 |
Eastman Kodak Company |
Process for buffering concentrated aqueous slurries
|
US5552154A
(en)
|
1989-11-06 |
1996-09-03 |
The Stehlin Foundation For Cancer Research |
Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
|
AU642066B2
(en)
*
|
1991-01-25 |
1993-10-07 |
Nanosystems L.L.C. |
X-ray contrast compositions useful in medical imaging
|
US5399363A
(en)
*
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
US5552160A
(en)
*
|
1991-01-25 |
1996-09-03 |
Nanosystems L.L.C. |
Surface modified NSAID nanoparticles
|
SE9101090D0
(sv)
*
|
1991-04-11 |
1991-04-11 |
Astra Ab |
Process for conditioning of water-soluble substances
|
US5766635A
(en)
*
|
1991-06-28 |
1998-06-16 |
Rhone-Poulenc Rorer S.A. |
Process for preparing nanoparticles
|
US5811447A
(en)
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6515009B1
(en)
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5342609A
(en)
*
|
1991-10-22 |
1994-08-30 |
Mallinckrodt Medical, Inc. |
Microfluidization of calcium/oxyanion-containing particles
|
US5407659A
(en)
*
|
1991-10-22 |
1995-04-18 |
Mallinckrodt Medical, Inc. |
Treated calcium/oxyanion-containing particles for medical diagnostic imaging
|
US5344640A
(en)
*
|
1991-10-22 |
1994-09-06 |
Mallinckrodt Medical, Inc. |
Preparation of apatite particles for medical diagnostic imaging
|
US5916540A
(en)
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
US7105152B1
(en)
|
1991-12-18 |
2006-09-12 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
EP0617610B1
(de)
*
|
1991-12-18 |
1997-03-19 |
Minnesota Mining And Manufacturing Company |
Aerosolzusammensetzungen für arzneimittelsuspensionen
|
US7101534B1
(en)
|
1991-12-18 |
2006-09-05 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
US6080751A
(en)
*
|
1992-01-14 |
2000-06-27 |
The Stehlin Foundation For Cancer Research |
Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
|
DK0644755T3
(da)
*
|
1992-06-10 |
1997-09-22 |
Nanosystems Llc |
Overflademodificerede NSAID-nanopartikler
|
US5552156A
(en)
*
|
1992-10-23 |
1996-09-03 |
Ohio State University |
Liposomal and micellular stabilization of camptothecin drugs
|
AU660852B2
(en)
*
|
1992-11-25 |
1995-07-06 |
Elan Pharma International Limited |
Method of grinding pharmaceutical substances
|
US5346702A
(en)
*
|
1992-12-04 |
1994-09-13 |
Sterling Winthrop Inc. |
Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
|
US5298262A
(en)
*
|
1992-12-04 |
1994-03-29 |
Sterling Winthrop Inc. |
Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
|
US5302401A
(en)
*
|
1992-12-09 |
1994-04-12 |
Sterling Winthrop Inc. |
Method to reduce particle size growth during lyophilization
|
US5340564A
(en)
*
|
1992-12-10 |
1994-08-23 |
Sterling Winthrop Inc. |
Formulations comprising olin 10-G to prevent particle aggregation and increase stability
|
US5336507A
(en)
*
|
1992-12-11 |
1994-08-09 |
Sterling Winthrop Inc. |
Use of charged phospholipids to reduce nanoparticle aggregation
|
US5429824A
(en)
*
|
1992-12-15 |
1995-07-04 |
Eastman Kodak Company |
Use of tyloxapole as a nanoparticle stabilizer and dispersant
|
US5322679A
(en)
*
|
1992-12-16 |
1994-06-21 |
Sterling Winthrop Inc. |
Iodinated aroyloxy esters
|
US5364550A
(en)
*
|
1992-12-16 |
1994-11-15 |
Eastman Kodak Company |
Liquid detergent composition
|
US5256328A
(en)
*
|
1992-12-16 |
1993-10-26 |
Eastman Kodak Company |
Liquid toilet bowl cleaner and sanitizer containing halogen donating nanoparticles
|
US5352459A
(en)
*
|
1992-12-16 |
1994-10-04 |
Sterling Winthrop Inc. |
Use of purified surface modifiers to prevent particle aggregation during sterilization
|
US5326552A
(en)
*
|
1992-12-17 |
1994-07-05 |
Sterling Winthrop Inc. |
Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
|
US5354564A
(en)
*
|
1992-12-18 |
1994-10-11 |
Eastman Kodak Company |
Personal care compositions
|
US6491938B2
(en)
|
1993-05-13 |
2002-12-10 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6663881B2
(en)
|
1993-01-28 |
2003-12-16 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5981568A
(en)
*
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
US5916596A
(en)
|
1993-02-22 |
1999-06-29 |
Vivorx Pharmaceuticals, Inc. |
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
|
FR2702160B1
(fr)
*
|
1993-03-02 |
1995-06-02 |
Biovecteurs As |
Vecteurs particulaires synthétiques et procédé de préparation.
|
US5849263A
(en)
*
|
1993-03-30 |
1998-12-15 |
Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
|
US5830436A
(en)
*
|
1993-03-30 |
1998-11-03 |
Duke University |
Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
|
US5840277A
(en)
*
|
1993-03-30 |
1998-11-24 |
Charlotte Hospital Authority |
Treatment of chronic pulmonary inflammation
|
CH686761A5
(de)
|
1993-05-27 |
1996-06-28 |
Sandoz Ag |
Galenische Formulierungen.
|
US5543158A
(en)
*
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
US5635206A
(en)
*
|
1994-01-20 |
1997-06-03 |
Hoffmann-La Roche Inc. |
Process for liposomes or proliposomes
|
US5468598A
(en)
*
|
1994-04-18 |
1995-11-21 |
Eastman Kodak Company |
Solid particle dispersions for imaging systems
|
DE69523971T2
(de)
*
|
1994-04-18 |
2002-08-29 |
Eastman Kodak Co |
Stabile wässrige Festteilchen-Dispersionen
|
US5513803A
(en)
*
|
1994-05-25 |
1996-05-07 |
Eastman Kodak Company |
Continuous media recirculation milling process
|
TW384224B
(en)
*
|
1994-05-25 |
2000-03-11 |
Nano Sys Llc |
Method of preparing submicron particles of a therapeutic or diagnostic agent
|
US5500331A
(en)
*
|
1994-05-25 |
1996-03-19 |
Eastman Kodak Company |
Comminution with small particle milling media
|
US5478705A
(en)
*
|
1994-05-25 |
1995-12-26 |
Eastman Kodak Company |
Milling a compound useful in imaging elements using polymeric milling media
|
US5587143A
(en)
*
|
1994-06-28 |
1996-12-24 |
Nanosystems L.L.C. |
Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
|
US6007845A
(en)
*
|
1994-07-22 |
1999-12-28 |
Massachusetts Institute Of Technology |
Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
|
US5626862A
(en)
*
|
1994-08-02 |
1997-05-06 |
Massachusetts Institute Of Technology |
Controlled local delivery of chemotherapeutic agents for treating solid tumors
|
US20110196039A9
(en)
*
|
1994-10-05 |
2011-08-11 |
Kaesemeyer Wayne H |
Controlled release arginine formulations
|
DE4440337A1
(de)
*
|
1994-11-11 |
1996-05-15 |
Dds Drug Delivery Services Ges |
Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
|
US5955108A
(en)
*
|
1994-12-16 |
1999-09-21 |
Quadrant Healthcare (Uk) Limited |
Cross-linked microparticles and their use as therapeutic vehicles
|
US6524557B1
(en)
*
|
1994-12-22 |
2003-02-25 |
Astrazeneca Ab |
Aerosol formulations of peptides and proteins
|
US5609998A
(en)
*
|
1994-12-29 |
1997-03-11 |
Eastman Kodak Company |
Process for dispersing concentrated aqueous slurries
|
US5466440A
(en)
*
|
1994-12-30 |
1995-11-14 |
Eastman Kodak Company |
Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
|
US5628981A
(en)
*
|
1994-12-30 |
1997-05-13 |
Nano Systems L.L.C. |
Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
|
US20020048596A1
(en)
*
|
1994-12-30 |
2002-04-25 |
Gregor Cevc |
Preparation for the transport of an active substance across barriers
|
US5585108A
(en)
*
|
1994-12-30 |
1996-12-17 |
Nanosystems L.L.C. |
Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
|
US5662883A
(en)
*
|
1995-01-10 |
1997-09-02 |
Nanosystems L.L.C. |
Microprecipitation of micro-nanoparticulate pharmaceutical agents
|
US5716642A
(en)
*
|
1995-01-10 |
1998-02-10 |
Nano Systems L.L.C. |
Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
|
US5665331A
(en)
*
|
1995-01-10 |
1997-09-09 |
Nanosystems L.L.C. |
Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
|
US5560932A
(en)
*
|
1995-01-10 |
1996-10-01 |
Nano Systems L.L.C. |
Microprecipitation of nanoparticulate pharmaceutical agents
|
US5569448A
(en)
*
|
1995-01-24 |
1996-10-29 |
Nano Systems L.L.C. |
Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
|
US5520904A
(en)
*
|
1995-01-27 |
1996-05-28 |
Mallinckrodt Medical, Inc. |
Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
|
US5571536A
(en)
*
|
1995-02-06 |
1996-11-05 |
Nano Systems L.L.C. |
Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
|
PT808154E
(pt)
*
|
1995-02-06 |
2001-06-29 |
Elan Pharma Int Ltd |
Formulacoes de compostos sob a forma de dispersoes em nanoparticulas em oleos ou acidos gordos digestiveis
|
US5665330A
(en)
*
|
1995-02-08 |
1997-09-09 |
Nano Systems Llc |
Dual purposed diagnostic/therapeutic agent having a tri-iodinated benzoyl group linked to a coumarin
|
US5503723A
(en)
*
|
1995-02-08 |
1996-04-02 |
Eastman Kodak Company |
Isolation of ultra small particles
|
US5622938A
(en)
*
|
1995-02-09 |
1997-04-22 |
Nano Systems L.L.C. |
Sugar base surfactant for nanocrystals
|
US5518738A
(en)
*
|
1995-02-09 |
1996-05-21 |
Nanosystem L.L.C. |
Nanoparticulate nsaid compositions
|
US5591456A
(en)
*
|
1995-02-10 |
1997-01-07 |
Nanosystems L.L.C. |
Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
|
US5573783A
(en)
*
|
1995-02-13 |
1996-11-12 |
Nano Systems L.L.C. |
Redispersible nanoparticulate film matrices with protective overcoats
|
US5543133A
(en)
*
|
1995-02-14 |
1996-08-06 |
Nanosystems L.L.C. |
Process of preparing x-ray contrast compositions containing nanoparticles
|
AU4867296A
(en)
*
|
1995-02-14 |
1996-09-04 |
Nanosystems L.L.C. |
Process of preparing lymphography contrast agents
|
US5510118A
(en)
*
|
1995-02-14 |
1996-04-23 |
Nanosystems Llc |
Process for preparing therapeutic compositions containing nanoparticles
|
US5580579A
(en)
*
|
1995-02-15 |
1996-12-03 |
Nano Systems L.L.C. |
Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
|
US5747001A
(en)
*
|
1995-02-24 |
1998-05-05 |
Nanosystems, L.L.C. |
Aerosols containing beclomethazone nanoparticle dispersions
|
US5565188A
(en)
*
|
1995-02-24 |
1996-10-15 |
Nanosystems L.L.C. |
Polyalkylene block copolymers as surface modifiers for nanoparticles
|
AU4990696A
(en)
*
|
1995-02-24 |
1996-09-11 |
Nanosystems L.L.C. |
Aerosols containing nanoparticle dispersions
|
US5736156A
(en)
*
|
1995-03-22 |
1998-04-07 |
The Ohio State University |
Liposomal anf micellular stabilization of camptothecin drugs
|
US5605696A
(en)
*
|
1995-03-30 |
1997-02-25 |
Advanced Cardiovascular Systems, Inc. |
Drug loaded polymeric material and method of manufacture
|
US6428771B1
(en)
*
|
1995-05-15 |
2002-08-06 |
Pharmaceutical Discovery Corporation |
Method for drug delivery to the pulmonary system
|
IL118088A0
(en)
*
|
1995-06-07 |
1996-08-04 |
Anzon Inc |
Colloidal particles of solid flame retardant and smoke suppressant compounds and methods for making them
|
ES2177592T3
(es)
*
|
1995-07-05 |
2002-12-16 |
Europ Economic Community |
Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos.
|
FR2736550B1
(fr)
|
1995-07-14 |
1998-07-24 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6391338B1
(en)
*
|
1995-09-07 |
2002-05-21 |
Biovail Technologies Ltd. |
System for rendering substantially non-dissoluble bio-affecting agents bio-available
|
US5834025A
(en)
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
EP0855906B1
(de)
|
1995-10-17 |
2008-02-20 |
Jagotec AG |
Verabreichung unlöslicher arzneistoffe
|
US5679138A
(en)
*
|
1995-11-30 |
1997-10-21 |
Eastman Kodak Company |
Ink jet inks containing nanoparticles of organic pigments
|
US5662279A
(en)
*
|
1995-12-05 |
1997-09-02 |
Eastman Kodak Company |
Process for milling and media separation
|
US20050267302A1
(en)
*
|
1995-12-11 |
2005-12-01 |
G.D. Searle & Co. |
Eplerenone crystalline form exhibiting enhanced dissolution rate
|
US5968543A
(en)
*
|
1996-01-05 |
1999-10-19 |
Advanced Polymer Systems, Inc. |
Polymers with controlled physical state and bioerodibility
|
US5686133A
(en)
*
|
1996-01-31 |
1997-11-11 |
Port Systems, L.L.C. |
Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
|
US5611344A
(en)
*
|
1996-03-05 |
1997-03-18 |
Acusphere, Inc. |
Microencapsulated fluorinated gases for use as imaging agents
|
HU226714B1
(en)
*
|
1996-03-05 |
2009-07-28 |
Acusphere |
Microencapsulated fluorinated gases for use as imaging agents
|
AU702955B2
(en)
*
|
1996-05-17 |
1999-03-11 |
Quadrant Healthcare (Uk) Limited |
Microparticles and their use in wound therapy
|
US5874064A
(en)
*
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
DK0914102T3
(da)
*
|
1996-05-24 |
2006-01-09 |
Angiotech Pharm Inc |
Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler
|
USRE37053E1
(en)
|
1996-05-24 |
2001-02-13 |
Massachusetts Institute Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
US6503480B1
(en)
*
|
1997-05-23 |
2003-01-07 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US6652837B1
(en)
*
|
1996-05-24 |
2003-11-25 |
Massachusetts Institute Of Technology |
Preparation of novel particles for inhalation
|
US20020052310A1
(en)
*
|
1997-09-15 |
2002-05-02 |
Massachusetts Institute Of Technology The Penn State Research Foundation |
Particles for inhalation having sustained release properties
|
US6254854B1
(en)
|
1996-05-24 |
2001-07-03 |
The Penn Research Foundation |
Porous particles for deep lung delivery
|
US5726154A
(en)
*
|
1996-06-28 |
1998-03-10 |
University Of Utah Research Foundation |
Stabilization and oral delivery of calcitonin
|
US5837221A
(en)
*
|
1996-07-29 |
1998-11-17 |
Acusphere, Inc. |
Polymer-lipid microencapsulated gases for use as imaging agents
|
US5935890A
(en)
|
1996-08-01 |
1999-08-10 |
Glcc Technologies, Inc. |
Stable dispersions of metal passivation agents and methods for making them
|
US7255877B2
(en)
*
|
1996-08-22 |
2007-08-14 |
Jagotec Ag |
Fenofibrate microparticles
|
US6465016B2
(en)
|
1996-08-22 |
2002-10-15 |
Research Triangle Pharmaceuticals |
Cyclosporiine particles
|
US7060253B1
(en)
*
|
1996-09-20 |
2006-06-13 |
Mundschenk David D |
Topical formulations and delivery systems
|
GB9622173D0
(en)
*
|
1996-10-24 |
1996-12-18 |
Glaxo Group Ltd |
Particulate Products
|
US6515016B2
(en)
|
1996-12-02 |
2003-02-04 |
Angiotech Pharmaceuticals, Inc. |
Composition and methods of paclitaxel for treating psoriasis
|
FR2758459B1
(fr)
*
|
1997-01-17 |
1999-05-07 |
Pharma Pass |
Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
|
US5993856A
(en)
*
|
1997-01-24 |
1999-11-30 |
Femmepharma |
Pharmaceutical preparations and methods for their administration
|
US6416778B1
(en)
|
1997-01-24 |
2002-07-09 |
Femmepharma |
Pharmaceutical preparations and methods for their regional administration
|
WO1998035666A1
(en)
*
|
1997-02-13 |
1998-08-20 |
Nanosystems Llc |
Formulations of nanoparticle naproxen tablets
|
US6045829A
(en)
|
1997-02-13 |
2000-04-04 |
Elan Pharma International Limited |
Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
|
CO4920215A1
(es)
*
|
1997-02-14 |
2000-05-29 |
Novartis Ag |
Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
US5989591A
(en)
*
|
1997-03-14 |
1999-11-23 |
American Home Products Corporation |
Rapamycin formulations for oral administration
|
US6193954B1
(en)
*
|
1997-03-21 |
2001-02-27 |
Abbott Laboratories |
Formulations for pulmonary delivery of dopamine agonists
|
AU7133898A
(en)
*
|
1997-04-18 |
1998-11-13 |
Vertex Pharmaceuticals Incorporated |
Nanosized aspartyl protease inhibitors
|
JP4672820B2
(ja)
|
1997-05-08 |
2011-04-20 |
メルク シャープ エンド ドーム リミテッド |
GABAα5リガンドとしての置換1,2,4−トリアゾロ[3,4−a]フタラジン誘導体
|
US7087713B2
(en)
*
|
2000-02-25 |
2006-08-08 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
IT1292142B1
(it)
*
|
1997-06-12 |
1999-01-25 |
Maria Rosa Gasco |
Composizione farmaceutica in forma di microparticelle lipidiche solide atte alla somministrazione parenterale
|
AU8145198A
(en)
*
|
1997-06-16 |
1999-01-04 |
Vertex Pharmaceuticals Incorporated |
Methods of increasing the bioavailability of stable crystal polymorphs of a compound
|
EP2272504A3
(de)
|
1997-06-27 |
2014-02-26 |
Abraxis BioScience, LLC |
Zusammensetzungen von pharmakologischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
|
CN100462066C
(zh)
*
|
1997-06-27 |
2009-02-18 |
美国生物科学有限公司 |
药剂的新制剂及其制备和应用方法
|
US7052678B2
(en)
|
1997-09-15 |
2006-05-30 |
Massachusetts Institute Of Technology |
Particles for inhalation having sustained release properties
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
US6309623B1
(en)
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US20020017295A1
(en)
*
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
US6946117B1
(en)
*
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6919070B1
(en)
*
|
1997-10-17 |
2005-07-19 |
Zakrytoe Aktsionernoe Obschestvo “OSTIM” |
Stomatic composition
|
UA72189C2
(uk)
*
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
|
GB9726543D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel compositions
|
US6086376A
(en)
*
|
1998-01-30 |
2000-07-11 |
Rtp Pharma Inc. |
Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
|
KR20010041234A
(ko)
|
1998-02-25 |
2001-05-15 |
더블유. 지. 콜 |
치환된 1,2,4-트리아졸로[3,4-a]피리다진
|
ZA991922B
(en)
*
|
1998-03-11 |
1999-09-13 |
Smithkline Beecham Corp |
Novel compositions of eprosartan.
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6337092B1
(en)
|
1998-03-30 |
2002-01-08 |
Rtp Pharma Inc. |
Composition and method of preparing microparticles of water-insoluble substances
|
EP1067914B1
(de)
*
|
1998-03-30 |
2006-02-22 |
Jagotec Ag |
Zubereitungen enthaltend mikropartikel von wasserunlöslichen substanzen, sowie verfahren zu deren herstellung
|
US6979456B1
(en)
|
1998-04-01 |
2005-12-27 |
Jagotec Ag |
Anticancer compositions
|
CA2333648C
(en)
|
1998-05-29 |
2008-10-21 |
Rtp Pharma Inc. |
Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
|
US6153225A
(en)
*
|
1998-08-13 |
2000-11-28 |
Elan Pharma International Limited |
Injectable formulations of nanoparticulate naproxen
|
US6956021B1
(en)
|
1998-08-25 |
2005-10-18 |
Advanced Inhalation Research, Inc. |
Stable spray-dried protein formulations
|
US6165506A
(en)
*
|
1998-09-04 |
2000-12-26 |
Elan Pharma International Ltd. |
Solid dose form of nanoparticulate naproxen
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
WO2000018374A1
(en)
*
|
1998-10-01 |
2000-04-06 |
Elan Pharma International, Ltd. |
Controlled release nanoparticulate compositions
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
US20040013613A1
(en)
*
|
2001-05-18 |
2004-01-22 |
Jain Rajeev A |
Rapidly disintegrating solid oral dosage form
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
JP4613275B2
(ja)
*
|
1998-11-02 |
2011-01-12 |
エラン ファーマ インターナショナル,リミティド |
多粒子改質放出組成物
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
US20070160675A1
(en)
*
|
1998-11-02 |
2007-07-12 |
Elan Corporation, Plc |
Nanoparticulate and controlled release compositions comprising a cephalosporin
|
US6375986B1
(en)
|
2000-09-21 |
2002-04-23 |
Elan Pharma International Ltd. |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
|
US7521068B2
(en)
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
JP2002529504A
(ja)
*
|
1998-11-12 |
2002-09-10 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
インスリン感作物質および他の抗糖尿病薬の放出修飾のための医薬組成物
|
GB9824897D0
(en)
|
1998-11-12 |
1999-01-06 |
Merck Sharp & Dohme |
Therapeutic compounds
|
US6428814B1
(en)
*
|
1999-10-08 |
2002-08-06 |
Elan Pharma International Ltd. |
Bioadhesive nanoparticulate compositions having cationic surface stabilizers
|
US6969529B2
(en)
*
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
ID29270A
(id)
|
1998-11-20 |
2001-08-16 |
Rtp Pharma Inc |
Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
EP2261335B1
(de)
*
|
1998-11-27 |
2017-06-14 |
UCB Pharma S.A. |
Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
|
DE19856432A1
(de)
*
|
1998-12-08 |
2000-06-15 |
Basf Ag |
Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
|
PT1031346E
(pt)
|
1999-01-27 |
2002-09-30 |
Idea Ag |
Vacinacao nao invasiva atraves da pele
|
SI1031347T1
(en)
|
1999-01-27 |
2002-10-31 |
Idea Ag |
Transnasal transport/immunisation with highly adaptable carriers
|
US7374779B2
(en)
*
|
1999-02-26 |
2008-05-20 |
Lipocine, Inc. |
Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
US6267985B1
(en)
*
|
1999-06-30 |
2001-07-31 |
Lipocine Inc. |
Clear oil-containing pharmaceutical compositions
|
US6761903B2
(en)
|
1999-06-30 |
2004-07-13 |
Lipocine, Inc. |
Clear oil-containing pharmaceutical compositions containing a therapeutic agent
|
US6270806B1
(en)
*
|
1999-03-03 |
2001-08-07 |
Elan Pharma International Limited |
Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
|
US6267989B1
(en)
*
|
1999-03-08 |
2001-07-31 |
Klan Pharma International Ltd. |
Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
|
EG23951A
(en)
|
1999-03-25 |
2008-01-29 |
Otsuka Pharma Co Ltd |
Cilostazol preparation
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
AU4225700A
(en)
*
|
1999-04-12 |
2000-11-14 |
Dow Agrosciences Llc |
Aqueous dispersions of agricultural chemicals
|
US6491239B2
(en)
|
1999-05-06 |
2002-12-10 |
Eastman Kodak Company |
Process for milling compounds
|
US6309749B1
(en)
|
1999-05-06 |
2001-10-30 |
Eastman Kodak Company |
Ceramic milling media containing tetragonal zirconia
|
US6444223B1
(en)
|
1999-05-28 |
2002-09-03 |
Alkermes Controlled Therapeutics, Inc. |
Method of producing submicron particles of a labile agent and use thereof
|
EP1185371B2
(de)
|
1999-06-01 |
2008-11-12 |
Elan Pharma International Limited |
Kleinmühle und verfahren dafür
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US20090104273A1
(en)
*
|
1999-06-22 |
2009-04-23 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
US9006175B2
(en)
*
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
EP2280020B1
(de)
*
|
1999-06-29 |
2016-02-17 |
MannKind Corporation |
Pharmazeutische zusammensetzungen enthaltend ein peptid welches mit diketopiperazin komplexiert ist.
|
US6982281B1
(en)
*
|
2000-11-17 |
2006-01-03 |
Lipocine Inc |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
US6458383B2
(en)
|
1999-08-17 |
2002-10-01 |
Lipocine, Inc. |
Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
AU5409699A
(en)
*
|
1999-07-05 |
2001-01-22 |
Idea Ag |
A method for the improvement of transport across adaptable semi-permeable barriers
|
US6576224B1
(en)
*
|
1999-07-06 |
2003-06-10 |
Sinuspharma, Inc. |
Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
|
FR2795961B1
(fr)
*
|
1999-07-09 |
2004-05-28 |
Ethypharm Lab Prod Ethiques |
Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
|
US7863331B2
(en)
|
1999-07-09 |
2011-01-04 |
Ethypharm |
Pharmaceutical composition containing fenofibrate and method for the preparation thereof
|
US6933318B1
(en)
|
1999-08-12 |
2005-08-23 |
Eli Lilly And Company |
Topical organic ectoparasiticidal formulations
|
US6927210B1
(en)
|
1999-08-12 |
2005-08-09 |
Eli Lilly And Company |
Ectoparasiticidal aqueous suspension formulations of spinosyns
|
KR100706146B1
(ko)
|
1999-08-12 |
2007-04-11 |
일라이 릴리 앤드 캄파니 |
외부기생충박멸용 스피노신을 사용한 애완동물의 경구치료법
|
JP2003507410A
(ja)
*
|
1999-08-25 |
2003-02-25 |
アドバンスト インハレーション リサーチ,インコーポレイテッド |
乾燥粉末製剤からの放出調節
|
US6749835B1
(en)
|
1999-08-25 |
2004-06-15 |
Advanced Inhalation Research, Inc. |
Formulation for spray-drying large porous particles
|
US7678364B2
(en)
|
1999-08-25 |
2010-03-16 |
Alkermes, Inc. |
Particles for inhalation having sustained release properties
|
US20010036481A1
(en)
*
|
1999-08-25 |
2001-11-01 |
Advanced Inhalation Research, Inc. |
Modulation of release from dry powder formulations
|
US6656504B1
(en)
|
1999-09-09 |
2003-12-02 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
|
WO2001024820A1
(en)
*
|
1999-10-07 |
2001-04-12 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
EP2269587A1
(de)
|
1999-10-29 |
2011-01-05 |
Euro-Celtique S.A. |
Hydrocodon-Formulierungen mit gesteuerter Freisetzung
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
US20030096798A1
(en)
*
|
1999-11-09 |
2003-05-22 |
Williams Gordon H. |
Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
|
US20030203884A1
(en)
*
|
1999-11-09 |
2003-10-30 |
Pharmacia Corporation |
Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
|
AUPQ441699A0
(en)
|
1999-12-02 |
2000-01-06 |
Eli Lilly And Company |
Pour-on formulations
|
EP1525883A1
(de)
*
|
1999-12-08 |
2005-04-27 |
Pharmacia Corporation |
Arzneizubereitungen mit schnellem Wirkungseintritt enthaltend einen Cyclooxygenase-2-Hemmer
|
US6251136B1
(en)
|
1999-12-08 |
2001-06-26 |
Advanced Cardiovascular Systems, Inc. |
Method of layering a three-coated stent using pharmacological and polymeric agents
|
NZ513962A
(en)
*
|
1999-12-08 |
2004-08-27 |
Pharmacia Corp |
Eplerenone crystalline form
|
US20030083493A1
(en)
*
|
1999-12-08 |
2003-05-01 |
Barton Kathleen P. |
Eplerenone drug substance having high phase purity
|
UA74539C2
(en)
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
US6702849B1
(en)
|
1999-12-13 |
2004-03-09 |
Advanced Cardiovascular Systems, Inc. |
Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
|
ES2240222T3
(es)
|
1999-12-20 |
2005-10-16 |
Nicholas J. Kerkhof |
Procedimiento para producir particulas nanometricas mediante secado por pulverizacion en lecho fluidizado.
|
US8771740B2
(en)
*
|
1999-12-20 |
2014-07-08 |
Nicholas J. Kerkhof |
Process for producing nanoparticles by spray drying
|
GB9930562D0
(en)
*
|
1999-12-23 |
2000-02-16 |
Boc Group Plc |
Partial oxidation of hydrogen sulphide
|
GEP20053427B
(en)
|
1999-12-23 |
2005-01-25 |
Pfizer Prod Inc |
Pharmaceutical Compositions Providing Enhanced Drug Concentrations
|
US7732404B2
(en)
|
1999-12-30 |
2010-06-08 |
Dexcel Ltd |
Pro-nanodispersion for the delivery of cyclosporin
|
AU774311B2
(en)
|
2000-01-31 |
2004-06-24 |
Lab21, Inc. |
Method and system for producing customized cosmetic and pharmaceutical formulations on demand
|
KR100848973B1
(ko)
|
2000-02-23 |
2008-07-30 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
종양 특이적 동물 단백질
|
CN1406140A
(zh)
*
|
2000-02-28 |
2003-03-26 |
吉倪塞思公司 |
纳米胶囊包封系统与方法
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
AUPQ634300A0
(en)
*
|
2000-03-20 |
2000-04-15 |
Eli Lilly And Company |
Synergistic formulations
|
US7153525B1
(en)
*
|
2000-03-22 |
2006-12-26 |
The University Of Kentucky Research Foundation |
Microemulsions as precursors to solid nanoparticles
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
EP1265849B1
(de)
|
2000-03-23 |
2006-10-25 |
Elan Pharmaceuticals, Inc. |
Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
|
GB0009773D0
(en)
*
|
2000-04-19 |
2000-06-07 |
Univ Cardiff |
Particulate composition
|
NZ522239A
(en)
|
2000-04-20 |
2004-03-26 |
Skyepharma Canada Inc |
Improved water-insoluble drug particle process
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
ATE389455T1
(de)
|
2000-05-10 |
2008-04-15 |
Jagotec Ag |
Zerkleinerung mittels mahlkörper
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
WO2001085136A2
(en)
|
2000-05-10 |
2001-11-15 |
Alliance Pharmaceutical Corporation |
Phospholipid-based powders for drug delivery
|
US6316029B1
(en)
*
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
US20040156872A1
(en)
*
|
2000-05-18 |
2004-08-12 |
Elan Pharma International Ltd. |
Novel nimesulide compositions
|
AR035642A1
(es)
|
2000-05-26 |
2004-06-23 |
Pharmacia Corp |
Uso de una composicion de celecoxib para el alivio rapido del dolor
|
AU6867801A
(en)
|
2000-06-20 |
2002-01-02 |
Corixa Corp |
Fusion proteins of mycobacterium tuberculosis
|
WO2002000650A2
(en)
*
|
2000-06-27 |
2002-01-03 |
Genelabs Technologies, Inc. |
Novel compounds possessing antibacterial, antifungal or antitumor activity
|
AU2001273149A1
(en)
|
2000-06-28 |
2002-01-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
EP1666452A2
(de)
|
2000-06-30 |
2006-06-07 |
Elan Pharmaceuticals, Inc. |
Verbindungen zur Behandlung der Alzheimerischen Krankheit
|
PE20020276A1
(es)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
|
US6846813B2
(en)
*
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
KR20030058959A
(ko)
*
|
2000-06-30 |
2003-07-07 |
엘란 파마슈티칼스, 인크. |
알츠하이머병을 치료하기 위한 화합물
|
IN192160B
(de)
*
|
2000-07-17 |
2004-02-28 |
Ranbaxy Lab |
|
US6656505B2
(en)
|
2000-07-21 |
2003-12-02 |
Alpharma Uspd Inc. |
Method for forming an aqueous flocculated suspension
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
AU2001279050B2
(en)
*
|
2000-07-27 |
2006-10-19 |
Pharmacia Corporation |
Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
|
US20020111337A1
(en)
*
|
2000-08-28 |
2002-08-15 |
Fedde Kenton N. |
Use of an aldosterone receptor antagonist to improve cognitive function
|
DE60137943D1
(de)
|
2000-08-31 |
2009-04-23 |
Jagotec Ag |
Gemahlene partikel
|
US8586094B2
(en)
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
US7198795B2
(en)
*
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
US7276249B2
(en)
*
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US7998507B2
(en)
*
|
2000-09-21 |
2011-08-16 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
|
US20030224058A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US20080241070A1
(en)
*
|
2000-09-21 |
2008-10-02 |
Elan Pharma International Ltd. |
Fenofibrate dosage forms
|
US20030181411A1
(en)
*
|
2002-03-20 |
2003-09-25 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
|
AU2738302A
(en)
|
2000-10-30 |
2002-05-15 |
Euro Celtique Sa |
Controlled release hydrocodone formulations
|
US8551526B2
(en)
*
|
2000-11-03 |
2013-10-08 |
Board Of Regents, The University Of Texas System |
Preparation of drug particles using evaporation precipitation into aqueous solutions
|
US6756062B2
(en)
|
2000-11-03 |
2004-06-29 |
Board Of Regents University Of Texas System |
Preparation of drug particles using evaporation precipitation into aqueous solutions
|
US20030198679A1
(en)
*
|
2000-11-08 |
2003-10-23 |
Kundu Subhas C. |
Flocculated pharmaceutical suspensions and methods for actives
|
WO2002058622A2
(en)
*
|
2000-11-09 |
2002-08-01 |
Neopharm, Inc. |
Sn-38 lipid complexes and methods of use
|
GB0028583D0
(en)
*
|
2000-11-23 |
2001-01-10 |
Merck Sharp & Dohme |
Therapeutic compounds
|
EP2298279B1
(de)
|
2000-11-30 |
2018-11-14 |
Vectura Limited |
Pharmazeutische Zusammensetzungen zur Inhalation
|
DE60140268D1
(de)
|
2000-11-30 |
2009-12-03 |
Vectura Ltd |
Partikel zur verwendung in einer pharmazeutischen zusammensetzung
|
JP2004518642A
(ja)
*
|
2000-12-06 |
2004-06-24 |
ファルマシア・コーポレーション |
ラボラトリースケールの微粉砕化プロセス
|
EP1350793A1
(de)
*
|
2000-12-11 |
2003-10-08 |
Takeda Chemical Industries, Ltd. |
Medizinische zusammensetzungen mit verbesserter absorbierbarkeit
|
DE10063090A1
(de)
*
|
2000-12-18 |
2002-06-20 |
Henkel Kgaa |
Nanoskaliges ZnO in Hygiene-Produkten
|
DE10063092A1
(de)
*
|
2000-12-18 |
2002-06-20 |
Henkel Kgaa |
Nanoskalige Materialien in Hygiene-Produkten
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
US20050048126A1
(en)
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US20030072807A1
(en)
*
|
2000-12-22 |
2003-04-17 |
Wong Joseph Chung-Tak |
Solid particulate antifungal compositions for pharmaceutical use
|
US7037528B2
(en)
*
|
2000-12-22 |
2006-05-02 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
WO2002055059A2
(en)
*
|
2000-12-22 |
2002-07-18 |
Baxter Int |
Method for preparing submicron particle suspensions
|
US8067032B2
(en)
*
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US6623761B2
(en)
|
2000-12-22 |
2003-09-23 |
Hassan Emadeldin M. |
Method of making nanoparticles of substantially water insoluble materials
|
US20040022862A1
(en)
*
|
2000-12-22 |
2004-02-05 |
Kipp James E. |
Method for preparing small particles
|
US6884436B2
(en)
*
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US9700866B2
(en)
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
US20020198254A1
(en)
*
|
2000-12-27 |
2002-12-26 |
Velligan Mark D. |
Polyamide analogs
|
US20020141946A1
(en)
*
|
2000-12-29 |
2002-10-03 |
Advanced Inhalation Research, Inc. |
Particles for inhalation having rapid release properties
|
EP1345629A2
(de)
*
|
2000-12-29 |
2003-09-24 |
Advanced Inhalation Research, Inc. |
Inhalationspartikel mit verzögerter freigabe
|
US20030125236A1
(en)
*
|
2000-12-29 |
2003-07-03 |
Advenced Inhalation Research, Inc. |
Particles for inhalation having rapid release properties
|
FI20010115A0
(fi)
*
|
2001-01-18 |
2001-01-18 |
Orion Corp |
Menetelmä nanopartikkelien valmistamiseksi
|
US20030053981A1
(en)
*
|
2001-01-26 |
2003-03-20 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
ATE348649T1
(de)
*
|
2001-01-26 |
2007-01-15 |
Schering Corp |
Kombinationen von einem hemmer der sterol- absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
|
SK9502003A3
(en)
*
|
2001-01-26 |
2003-12-02 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
MXPA03006724A
(es)
*
|
2001-01-26 |
2003-10-24 |
Schering Corp |
Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares.
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
RU2756946C2
(ru)
*
|
2001-01-26 |
2021-10-07 |
Мерк Шарп И Доум Корп. |
Применение замещенных азетидинонов для лечения ситостеролемии
|
EP1671650A1
(de)
*
|
2001-01-26 |
2006-06-21 |
Schering Corporation |
Kombinationen von einem Hemmer der Sterol-Absorption und Nicotinsäure zur Behandlung von kardiovaskulären Indikationen
|
US20040022861A1
(en)
*
|
2001-01-30 |
2004-02-05 |
Williams Robert O. |
Process for production of nanoparticles and microparticles by spray freezing into liquid
|
EP1357900A2
(de)
*
|
2001-01-30 |
2003-11-05 |
Board of Regents, The University of Texas System |
Herstellungsprozess von nanopartikeln und mikropartikeln durch sprühgefrierung in flüssigkeit
|
US20020150615A1
(en)
*
|
2001-02-12 |
2002-10-17 |
Howard Sands |
Injectable pharmaceutical composition comprising microdroplets of a camptothecin
|
US6497896B2
(en)
|
2001-02-12 |
2002-12-24 |
Supergen, Inc. |
Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
|
US6509027B2
(en)
|
2001-02-12 |
2003-01-21 |
Supergen, Inc. |
Injectable pharmaceutical composition comprising coated particles of camptothecin
|
JP3386052B2
(ja)
*
|
2001-02-13 |
2003-03-10 |
トヨタ自動車株式会社 |
ポンプ装置
|
PL213327B1
(pl)
|
2001-02-14 |
2013-02-28 |
Tibotec Pharm Ltd |
Zwiazki 2-(podstawione-amino)-benzotiazolosulfonamidowe, sposób ich wytwarzania oraz ich zastosowanie
|
JP2004523552A
(ja)
*
|
2001-02-22 |
2004-08-05 |
スカイファーマ・カナダ・インコーポレーテッド |
低減した摂食−絶食効果を伴うフィブラート−スタチンの組合わせ
|
NZ528363A
(en)
*
|
2001-04-03 |
2005-04-29 |
Schering Corp |
Liquid suspensions of posaconazole ( SCH 56592 ) with enhanced bioavailability for treating fungal infections
|
EP1392245A2
(de)
*
|
2001-04-05 |
2004-03-03 |
Universite Laval |
Verfahren zur herstellung von protein partikeln und ihre verwendung als trägermaterial
|
EE05384B1
(et)
|
2001-04-09 |
2011-02-15 |
Tibotec�Pharmaceuticals�Ltd. |
LaiaspektrilisedÁ2-(asendatudÁamino)bensoksasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁkasutamine,ÁfarmatseutilineÁkompositsioonÁjaÁmeetodÁretroviiruseÁreplikatsiooniÁinhibeerimiseks
|
US20040126900A1
(en)
*
|
2001-04-13 |
2004-07-01 |
Barry Stephen E |
High affinity peptide- containing nanoparticles
|
US6667344B2
(en)
|
2001-04-17 |
2003-12-23 |
Dey, L.P. |
Bronchodilating compositions and methods
|
US20030157161A1
(en)
*
|
2001-05-01 |
2003-08-21 |
Angiotech Pharmaceuticals, Inc. |
Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
|
JP2004529934A
(ja)
*
|
2001-05-01 |
2004-09-30 |
アンジオテック ファーマシューティカルズ,インコーポレイテッド |
抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用
|
ITMO20010086A1
(it)
*
|
2001-05-08 |
2002-11-08 |
Worgas Bruciatori Srl |
Metodo ed apparato per ridurre le emissioni di biossido di azoto (no2)in un apparecchio da riscaldamento senza canna fumaria
|
CA2446788A1
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
AP1652A
(en)
|
2001-05-11 |
2006-08-11 |
Tibotec Pharm Ltd |
Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors.
|
DE10125290B4
(de)
*
|
2001-05-15 |
2005-04-14 |
Siemens Ag |
Verfahren zum Aufbereiten von Nano-Dispersanten
|
US7152819B2
(en)
*
|
2001-05-23 |
2006-12-26 |
E. I. Du Pont De Nemours And Company |
High pressure media mill
|
WO2002096415A2
(en)
*
|
2001-05-25 |
2002-12-05 |
Schering Corporation |
Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
|
WO2003030864A1
(en)
*
|
2001-05-29 |
2003-04-17 |
Neopharm, Inc. |
Liposomal formulation of irinotecan
|
ES2309177T3
(es)
*
|
2001-06-05 |
2008-12-16 |
Elan Pharma International Limited |
Sistema y metodo para moler materiales.
|
US6976647B2
(en)
*
|
2001-06-05 |
2005-12-20 |
Elan Pharma International, Limited |
System and method for milling materials
|
US6730319B2
(en)
|
2001-06-06 |
2004-05-04 |
Hoffmann-La Roche Inc. |
Pharmaceutical compositions having depressed melting points
|
US20040173147A1
(en)
*
|
2001-06-07 |
2004-09-09 |
Figueroa Iddys D. |
Application of a bioactive agent to a delivery substrate
|
US6962715B2
(en)
*
|
2001-10-24 |
2005-11-08 |
Hewlett-Packard Development Company, L.P. |
Method and dosage form for dispensing a bioactive substance
|
US20040173146A1
(en)
*
|
2001-06-07 |
2004-09-09 |
Figueroa Iddys D. |
Application of a bioactive agent to a delivery substrate
|
JP2004532894A
(ja)
|
2001-06-13 |
2004-10-28 |
イーラン ファーマスーティカルズ、インコーポレイテッド |
アルツハイマー病を治療するためのアミンジオール
|
GB0114532D0
(en)
*
|
2001-06-14 |
2001-08-08 |
Jagotec Ag |
Novel compositions
|
EP1269994A3
(de)
*
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
|
DE60203506T2
(de)
*
|
2001-06-22 |
2006-02-16 |
Marie Lindner |
Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
|
BR0211028A
(pt)
*
|
2001-06-22 |
2004-06-15 |
Pfizer Prod Inc |
Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto
|
US7758890B2
(en)
|
2001-06-23 |
2010-07-20 |
Lyotropic Therapeutics, Inc. |
Treatment using dantrolene
|
BR0210721A
(pt)
*
|
2001-06-27 |
2004-07-20 |
Elan Pharm Inc |
Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
|
CA2453444A1
(en)
*
|
2001-07-10 |
2003-01-23 |
Elan Pharmaceuticals, Inc. |
Diaminediols for the treatment of alzheimer's disease
|
WO2003006453A1
(en)
*
|
2001-07-10 |
2003-01-23 |
Elan Pharmaceuticals, Inc. |
Aminediols for the treatment of alzheimer's disease
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
US20030220310A1
(en)
*
|
2001-07-27 |
2003-11-27 |
Schuh Joseph R. |
Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
|
US20080305173A1
(en)
*
|
2001-07-31 |
2008-12-11 |
Beuford Arlie Bogue |
Amorphous drug beads
|
ATE365537T1
(de)
*
|
2001-08-06 |
2007-07-15 |
Astrazeneca Ab |
Wässrige dispersion stabiler nanopartikel eines wasserunlöslichen wirkstoffs und ein hilfsstoff wie mittelkettige triglyceride (mct)
|
GB0119480D0
(en)
*
|
2001-08-09 |
2001-10-03 |
Jagotec Ag |
Novel compositions
|
MY169670A
(en)
|
2003-09-03 |
2019-05-08 |
Tibotec Pharm Ltd |
Combinations of a pyrimidine containing nnrti with rt inhibitors
|
DE60214012T2
(de)
*
|
2001-08-29 |
2006-12-21 |
Dow Global Technologies, Inc., Midland |
Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
AU2001291478B2
(en)
*
|
2001-09-17 |
2008-01-03 |
Elanco Us Inc. |
Pesticidal formulations
|
JP4464129B2
(ja)
*
|
2001-09-19 |
2010-05-19 |
エラン ファーマ インターナショナル,リミティド |
ナノ粒子インスリン製剤
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
JP2005504091A
(ja)
*
|
2001-09-21 |
2005-02-10 |
シェーリング コーポレイション |
ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
|
BR0212907A
(pt)
*
|
2001-09-21 |
2004-10-13 |
Schering Corp |
Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
MXPA04002762A
(es)
*
|
2001-09-25 |
2004-06-29 |
Pharmacia Corp |
Formas de estado solido de n-(2 -hidroxiacetil) -5-(4-piperidil) -4-(4-pirimidinil) -3-(4-clorofenil) pirazol.
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
IL160570A0
(en)
|
2001-09-26 |
2004-07-25 |
Baxter Int |
Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
|
US7544681B2
(en)
*
|
2001-09-27 |
2009-06-09 |
Ramot At Tel Aviv University Ltd. |
Conjugated psychotropic drugs and uses thereof
|
US20050233003A1
(en)
*
|
2001-09-28 |
2005-10-20 |
Solubest Ltd. |
Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
|
US20050227911A1
(en)
*
|
2001-09-28 |
2005-10-13 |
Solubest Ltd. |
Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
|
US20050191359A1
(en)
*
|
2001-09-28 |
2005-09-01 |
Solubest Ltd. |
Water soluble nanoparticles and method for their production
|
US6878693B2
(en)
*
|
2001-09-28 |
2005-04-12 |
Solubest Ltd. |
Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
|
US7244755B2
(en)
|
2001-10-04 |
2007-07-17 |
Pharmacia & Upjohn Company |
Hydroxypropylamines
|
US6908626B2
(en)
*
|
2001-10-12 |
2005-06-21 |
Elan Pharma International Ltd. |
Compositions having a combination of immediate release and controlled release characteristics
|
AU2002362836B2
(en)
*
|
2001-10-15 |
2008-05-22 |
Crititech, Inc. |
Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
TWI330183B
(de)
*
|
2001-10-22 |
2010-09-11 |
Eisai R&D Man Co Ltd |
|
WO2003039601A1
(en)
*
|
2001-11-07 |
2003-05-15 |
Imcor Pharmaceutical Company |
Methods for vascular imaging using nanoparticulate contrast agents
|
BR0214035A
(pt)
*
|
2001-11-08 |
2005-04-26 |
Elan Pharm Inc |
Composto
|
US7700851B2
(en)
*
|
2001-11-13 |
2010-04-20 |
U.S. Smokeless Tobacco Company |
Tobacco nicotine demethylase genomic clone and uses thereof
|
EP1448177A1
(de)
*
|
2001-11-19 |
2004-08-25 |
Elan Pharmaceuticals, Inc. |
Aminodiole zur behandlung von alzheimische krankheit
|
AU2002346472A1
(en)
*
|
2001-11-20 |
2003-06-10 |
Advanced Inhalation Research, Inc. |
Particulate compositions for improving solubility of poorly soluble agents
|
GB0127805D0
(en)
*
|
2001-11-20 |
2002-01-09 |
Smithkline Beecham Plc |
Pharmaceutical composition
|
US7182961B2
(en)
*
|
2001-11-20 |
2007-02-27 |
Advanced Inhalation Research, Inc. |
Particulate compositions for pulmonary delivery
|
UA76810C2
(uk)
*
|
2001-12-10 |
2006-09-15 |
Мерк Енд Ко., Інк. |
Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
|
DK2224012T3
(da)
|
2001-12-17 |
2013-05-13 |
Corixa Corp |
Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
|
TWI324518B
(en)
|
2001-12-19 |
2010-05-11 |
Nektar Therapeutics |
Pulmonary delivery of aminoglycosides
|
WO2003053292A1
(en)
*
|
2001-12-20 |
2003-07-03 |
Femmepharma, Inc. |
Vaginal delivery of drugs
|
JP2005513145A
(ja)
*
|
2001-12-21 |
2005-05-12 |
セラター テクノロジーズ インコーポレイテッド |
改変されたポリマー脂質送達ビヒクル
|
CA2470964C
(en)
|
2001-12-21 |
2013-07-02 |
Tibotec Pharmaceuticals Ltd. |
Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
|
US20030235619A1
(en)
*
|
2001-12-21 |
2003-12-25 |
Christine Allen |
Polymer-lipid delivery vehicles
|
BR0207583A
(pt)
*
|
2001-12-26 |
2004-04-27 |
Genelabs Tech Inc |
Derivados de poliamida possuindo atividade antibacteriana, antifungo ou antitumor
|
US20030129242A1
(en)
*
|
2002-01-04 |
2003-07-10 |
Bosch H. William |
Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
|
AU2003235686A1
(en)
*
|
2002-01-14 |
2003-07-30 |
Dow Global Technologies Inc. |
Drug nanoparticles from template emulsions
|
EP1474144B1
(de)
|
2002-02-01 |
2008-08-06 |
Pfizer Products Inc. |
Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
|
EP1478648B1
(de)
|
2002-02-01 |
2014-04-30 |
ARIAD Pharmaceuticals, Inc. |
Phosphorhaltige verbindungen und deren verwendungen
|
ATE464880T1
(de)
*
|
2002-02-04 |
2010-05-15 |
Elan Pharma Int Ltd |
Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
|
US7026465B2
(en)
|
2002-02-15 |
2006-04-11 |
Corixa Corporation |
Fusion proteins of Mycobacterium tuberculosis
|
MY142238A
(en)
|
2002-03-12 |
2010-11-15 |
Tibotec Pharm Ltd |
Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
|
GB0206200D0
(en)
*
|
2002-03-15 |
2002-05-01 |
Glaxo Group Ltd |
Pharmaceutical compositions
|
EP1494732B1
(de)
|
2002-03-20 |
2008-01-30 |
MannKind Corporation |
Inhalationsgerät
|
EP1800666A1
(de)
*
|
2002-03-20 |
2007-06-27 |
Elan Pharma International Limited |
Nanopartikelzusammensetzungen von Angiogeneseinhibitoren
|
JP2005526095A
(ja)
*
|
2002-03-20 |
2005-09-02 |
エラン ファーマ インターナショナル,リミティド |
脆砕性の低い急速溶解投与剤型
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
WO2003080027A1
(en)
†
|
2002-03-20 |
2003-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
US20040076586A1
(en)
*
|
2002-03-28 |
2004-04-22 |
Reinhard Koening |
Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
|
WO2003087763A2
(en)
|
2002-04-03 |
2003-10-23 |
Celltech R & D, Inc. |
Association of polymorphisms in the sost gene region with bone mineral density
|
US20040038303A1
(en)
*
|
2002-04-08 |
2004-02-26 |
Unger Gretchen M. |
Biologic modulations with nanoparticles
|
US20040105889A1
(en)
*
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
US7101576B2
(en)
*
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
PT1494649E
(pt)
*
|
2002-04-12 |
2012-04-11 |
Alkermes Pharma Ireland Ltd |
Formulações de megestrol em nanopartículas
|
US9101540B2
(en)
|
2002-04-12 |
2015-08-11 |
Alkermes Pharma Ireland Limited |
Nanoparticulate megestrol formulations
|
US20100226989A1
(en)
*
|
2002-04-12 |
2010-09-09 |
Elan Pharma International, Limited |
Nanoparticulate megestrol formulations
|
US7582284B2
(en)
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
DE10218109A1
(de)
*
|
2002-04-23 |
2003-11-20 |
Jenapharm Gmbh |
Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
|
WO2003090717A1
(en)
*
|
2002-04-23 |
2003-11-06 |
Nanotherapeutics, Inc |
Process of forming and modifying particles and compositions produced thereby
|
AU2003303141A1
(en)
*
|
2002-04-30 |
2004-07-22 |
Elan Pharmaceuticals, Inc. |
Hydroxypropyl amides for the treatment of alzheimer's disease
|
DE60325718D1
(de)
*
|
2002-05-06 |
2009-02-26 |
Elan Pharma Int Ltd |
Nystatin-nanopartikelzusammensetzungen
|
EP1517899B1
(de)
|
2002-05-17 |
2007-08-29 |
Tibotec Pharmaceuticals Ltd. |
Substituierte benzisoxazolsulfonamide mit breitbändiger hiv-protease hemmender wirkung
|
US8313760B2
(en)
|
2002-05-24 |
2012-11-20 |
Angiotech International Ag |
Compositions and methods for coating medical implants
|
ATE515277T1
(de)
|
2002-05-24 |
2011-07-15 |
Angiotech Int Ag |
Zusammensetzungen und verfahren zum beschichten von medizinischen implantaten
|
US20070264348A1
(en)
*
|
2002-05-24 |
2007-11-15 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US7763278B2
(en)
*
|
2002-06-10 |
2010-07-27 |
Elan Pharma International Ltd. |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
EP1531799A1
(de)
*
|
2002-06-10 |
2005-05-25 |
Elan Pharma International Limited |
Pharmazeutische nanopartikel-formulierungen mit hmg-coa-reduktase-inhibitoren ("statine"), neue kombinationen davon sowie herstellung dieser pharmazeutischen zusammensetzungen
|
CA2492488A1
(en)
|
2002-07-16 |
2004-01-22 |
Elan Pharma International, Ltd. |
Liquid dosage compositions of stable nanoparticulate active agents
|
GB0216700D0
(en)
*
|
2002-07-18 |
2002-08-28 |
Astrazeneca Ab |
Process
|
US20030017208A1
(en)
*
|
2002-07-19 |
2003-01-23 |
Francis Ignatious |
Electrospun pharmaceutical compositions
|
AR040588A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
AU2002950426A0
(en)
*
|
2002-07-29 |
2002-09-12 |
Patrick John Shanahan |
Anti microbial oro-dental system
|
DE10234784A1
(de)
*
|
2002-07-30 |
2004-02-19 |
Günenthal GmbH |
Intravenös applizierbare, pharmazeutische Darreichungsform
|
US7838034B2
(en)
|
2002-07-30 |
2010-11-23 |
Grunenthal Gmbh |
Intravenous pharmaceutical form of administration
|
US20040023935A1
(en)
*
|
2002-08-02 |
2004-02-05 |
Dey, L.P. |
Inhalation compositions, methods of use thereof, and process for preparation of same
|
US20040028747A1
(en)
*
|
2002-08-06 |
2004-02-12 |
Tucker Christopher J. |
Crystalline drug particles prepared using a controlled precipitation process
|
US20040028746A1
(en)
*
|
2002-08-06 |
2004-02-12 |
Sonke Svenson |
Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
|
WO2004014342A1
(en)
|
2002-08-12 |
2004-02-19 |
Pfizer Products Inc. |
Pharmaceutical compositions of semi-ordered drugs and polymers
|
EA010486B1
(ru)
|
2002-08-14 |
2008-10-30 |
Тиботек Фармасьютикалз Лтд. |
Замещенные оксиндолсульфонамидные ингибиторы вич-протеазы широкого спектра действия
|
US7445796B2
(en)
*
|
2002-08-19 |
2008-11-04 |
L. Perrigo Company |
Pharmaceutically active particles of a monomodal particle size distribution and method
|
US20060030578A1
(en)
*
|
2002-08-20 |
2006-02-09 |
Neopharm, Inc. |
Pharmaceutically active lipid based formulation of irinotecan
|
AU2003296897A1
(en)
*
|
2002-08-20 |
2004-05-04 |
Neopharm, Inc. |
Pharmaceutical formulations of camptothecine derivatives
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
AU2003262911A1
(en)
*
|
2002-08-29 |
2004-03-19 |
Scios Inc. |
Methods of promoting osteogenesis
|
US20060167069A1
(en)
*
|
2002-09-02 |
2006-07-27 |
Sun Pharmaceutical Industries Ltd. |
Pharmaceutical composition of metaxalone with enhanced oral bioavailability
|
EP1553927B9
(de)
*
|
2002-09-11 |
2011-09-21 |
Elan Pharma International Limited |
Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
|
US20060189554A1
(en)
*
|
2002-09-24 |
2006-08-24 |
Russell Mumper |
Nanoparticle-Based vaccine delivery system containing adjuvant
|
US20040105778A1
(en)
*
|
2002-10-04 |
2004-06-03 |
Elan Pharma International Limited |
Gamma irradiation of solid nanoparticulate active agents
|
US20040105881A1
(en)
*
|
2002-10-11 |
2004-06-03 |
Gregor Cevc |
Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
|
US20080145424A1
(en)
*
|
2002-10-24 |
2008-06-19 |
Enos Phramaceuticals, Inc. |
Sustained release L-arginine formulations and methods of manufacture and use
|
NZ539672A
(en)
*
|
2002-10-24 |
2006-09-29 |
Enos Pharmaceuticals Inc |
Sustained release L-arginine-formulations and methods of manufacture and use
|
US20040092499A1
(en)
*
|
2002-11-06 |
2004-05-13 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of autoimmune disorders
|
ATE514418T1
(de)
*
|
2002-11-12 |
2011-07-15 |
Elan Pharma Int Ltd |
Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
|
GB0227443D0
(en)
*
|
2002-11-25 |
2002-12-31 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
CA2507484A1
(en)
|
2002-11-27 |
2004-06-17 |
Elan Pharmaceuticals, Inc. |
Substituted ureas and carbamates
|
DK1569912T3
(en)
|
2002-12-03 |
2015-06-29 |
Pharmacyclics Inc |
2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
|
US20050095267A1
(en)
*
|
2002-12-04 |
2005-05-05 |
Todd Campbell |
Nanoparticle-based controlled release polymer coatings for medical implants
|
CA2511763A1
(en)
*
|
2002-12-06 |
2004-06-24 |
Scios Inc. |
Methods for treating diabetes
|
US20040109826A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Dey, L.P. |
Stabilized albuterol compositions and method of preparation thereof
|
AU2002356294A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Jagotec Ag |
A topical nanoparticulate spironolactone formulation
|
WO2004058216A2
(en)
*
|
2002-12-17 |
2004-07-15 |
Elan Pharma International Ltd. |
Milling microgram quantities of nanoparticulate candidate compounds
|
EP2474631B1
(de)
|
2002-12-20 |
2014-02-12 |
Celera Corporation |
Mit Myokardinfarkt assoziierte genetische Polymorphismen, Nachweisverfahren und deren Verwendungen
|
GB0230088D0
(en)
*
|
2002-12-24 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
GB0230087D0
(en)
*
|
2002-12-24 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
US9173836B2
(en)
|
2003-01-02 |
2015-11-03 |
FemmeParma Holding Company, Inc. |
Pharmaceutical preparations for treatments of diseases and disorders of the breast
|
WO2004060322A2
(en)
*
|
2003-01-02 |
2004-07-22 |
Femmepharma Holding Company, Inc. |
Pharmaceutical preparations for treatments of diseases and disorders of the breast
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
ES2556970T3
(es)
|
2003-01-06 |
2016-01-21 |
Corixa Corporation |
Ciertos compuestos de fosfato de aminoalquil glucosaminida y sus usos
|
JP4469846B2
(ja)
*
|
2003-01-31 |
2010-06-02 |
エラン ファーマ インターナショナル,リミティド |
ナノ粒子状トピラメート製剤
|
US20040208833A1
(en)
*
|
2003-02-04 |
2004-10-21 |
Elan Pharma International Ltd. |
Novel fluticasone formulations
|
GB0302673D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
GB0302672D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
GB0302671D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
US20100297252A1
(en)
|
2003-03-03 |
2010-11-25 |
Elan Pharma International Ltd. |
Nanoparticulate meloxicam formulations
|
US8512727B2
(en)
*
|
2003-03-03 |
2013-08-20 |
Alkermes Pharma Ireland Limited |
Nanoparticulate meloxicam formulations
|
JP2006519869A
(ja)
|
2003-03-07 |
2006-08-31 |
シェーリング コーポレイション |
置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
ES2318274T3
(es)
|
2003-03-07 |
2009-05-01 |
Schering Corporation |
Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
|
EP1601668B1
(de)
|
2003-03-07 |
2008-08-27 |
Schering Corporation |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
US20040184995A1
(en)
*
|
2003-03-17 |
2004-09-23 |
Yamanouchi Pharmaceutical Co., Ltd. |
Novel dry powder inhalation for lung-delivery and manufacturing method thereof
|
JP2006521366A
(ja)
*
|
2003-03-28 |
2006-09-21 |
シグモイド・バイオテクノロジーズ・リミテッド |
シームレスマイクロカプセルを含む固形経口剤形
|
EP2345329B1
(de)
*
|
2003-04-09 |
2019-09-18 |
Koppers Performance Chemicals Inc. |
Mikronisierte formulierungen zur holzkonservierung
|
US8747908B2
(en)
|
2003-04-09 |
2014-06-10 |
Osmose, Inc. |
Micronized wood preservative formulations
|
US8637089B2
(en)
|
2003-04-09 |
2014-01-28 |
Osmose, Inc. |
Micronized wood preservative formulations
|
CL2004000848A1
(es)
*
|
2003-04-21 |
2005-01-28 |
Elan Pharmaceuticals Inc Pharm |
Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
|
EP1615892A2
(de)
|
2003-04-21 |
2006-01-18 |
Elan Pharmaceuticals, Inc. |
Benzamid-2-hydroxy-3-diaminoalkane
|
AU2004240640A1
(en)
*
|
2003-05-19 |
2004-12-02 |
Baxter International Inc. |
Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
|
JP2006526007A
(ja)
*
|
2003-05-20 |
2006-11-16 |
ロレアル |
二酸コポリマーで寸法安定化された粒子
|
FR2855051B1
(fr)
*
|
2003-05-20 |
2006-08-25 |
Oreal |
Particules stabilisees en taille par copolymere diacide
|
CA2523035C
(en)
*
|
2003-05-22 |
2011-04-26 |
Elan Pharma International Ltd. |
Sterilization of dispersions of nanoparticulate active agents with gamma radiation
|
WO2004103347A2
(en)
*
|
2003-05-22 |
2004-12-02 |
Applied Nanosystems B.V. |
Production of small particles
|
US7459146B2
(en)
*
|
2003-05-30 |
2008-12-02 |
3M Innovative Properties Company |
Stabilized aerosol dispersions
|
US7109247B2
(en)
*
|
2003-05-30 |
2006-09-19 |
3M Innovative Properties Company |
Stabilized particle dispersions containing nanoparticles
|
DE10325989A1
(de)
*
|
2003-06-07 |
2005-01-05 |
Glatt Gmbh |
Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
|
NZ544618A
(en)
*
|
2003-06-16 |
2009-02-28 |
Celltech R & D Inc |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
JP4971790B2
(ja)
|
2003-06-17 |
2012-07-11 |
オズモウズ,インコーポレーテッド |
微粒子状木材保存剤及びその製造方法
|
JP2006527770A
(ja)
*
|
2003-06-18 |
2006-12-07 |
アストラゼネカ アクチボラグ |
Cb1モジュレーターとしての2−置換5,6−ジアリール−ピラジン誘導体
|
GB0314057D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314261D0
(en)
*
|
2003-06-19 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
US9044381B2
(en)
*
|
2003-06-24 |
2015-06-02 |
Baxter International Inc. |
Method for delivering drugs to the brain
|
US8986736B2
(en)
*
|
2003-06-24 |
2015-03-24 |
Baxter International Inc. |
Method for delivering particulate drugs to tissues
|
TWI359675B
(en)
|
2003-07-10 |
2012-03-11 |
Dey L P |
Bronchodilating β-agonist compositions
|
US8308682B2
(en)
|
2003-07-18 |
2012-11-13 |
Broncus Medical Inc. |
Devices for maintaining patency of surgically created channels in tissue
|
US20050042177A1
(en)
*
|
2003-07-23 |
2005-02-24 |
Elan Pharma International Ltd. |
Novel compositions of sildenafil free base
|
EP1652515A1
(de)
*
|
2003-08-06 |
2006-05-03 |
Eisai Co., Ltd. |
Verfahren zur herstellung von arzneiultramikropartikeln und vorrichtung dafür
|
WO2005016310A1
(en)
*
|
2003-08-08 |
2005-02-24 |
Elan Pharma International Ltd. |
Novel metaxalone compositions
|
US7419996B2
(en)
*
|
2003-08-13 |
2008-09-02 |
The University Of Houston |
Parenteral and oral formulations of benzimidazoles
|
GB0319797D0
(en)
*
|
2003-08-26 |
2003-09-24 |
Leuven K U Res & Dev |
Particle size reduction of poorly soluble drugs
|
US9149440B2
(en)
*
|
2003-09-02 |
2015-10-06 |
University Of South Florida |
Nanoparticles for drug-delivery
|
WO2005020929A2
(en)
*
|
2003-09-02 |
2005-03-10 |
Imran Ahmed |
Sustained release dosage forms of ziprasidone
|
EP1667675B1
(de)
|
2003-09-11 |
2011-11-09 |
Tibotec Pharmaceuticals |
Mittel zur hemmung des eintritts des hiv-virus
|
GB0327723D0
(en)
*
|
2003-09-15 |
2003-12-31 |
Vectura Ltd |
Pharmaceutical compositions
|
SG135189A1
(en)
|
2003-09-22 |
2007-09-28 |
Baxter Int |
High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
|
AU2004279298B2
(en)
*
|
2003-09-29 |
2009-01-29 |
Palmetto Pharmaceuticals, Llc |
Sustained release L-arginine formulations and methods of manufacture and use
|
WO2005032551A1
(en)
*
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
|
ES2284068T3
(es)
*
|
2003-10-16 |
2007-11-01 |
Teva Pharmaceutical Industries Limited |
Preparacion de candesartan cilexetilo.
|
US7338171B2
(en)
*
|
2003-10-27 |
2008-03-04 |
Jen-Chuen Hsieh |
Method and apparatus for visual drive control
|
EP1684725A1
(de)
*
|
2003-10-31 |
2006-08-02 |
Elan Pharma International Limited |
Neue nimesulid-zusammensetzungen
|
EP1686962B9
(de)
*
|
2003-11-05 |
2012-10-03 |
Elan Pharma International Limited |
Nanoteilchenförmige zusammensetzungen mit einem peptid als oberflächenstabilisator
|
US20050096307A1
(en)
*
|
2003-11-05 |
2005-05-05 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
EP1687043A2
(de)
*
|
2003-11-20 |
2006-08-09 |
Angiotech International Ag |
Elektrische vorrichtungen und anti-narben-mittel
|
CZ300438B6
(cs)
*
|
2003-11-25 |
2009-05-20 |
Pliva Hrvatska D.O.O. |
Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
|
US20050258288A1
(en)
*
|
2003-11-26 |
2005-11-24 |
E. I. Du Pont De Nemours And Company |
High pressure media milling system and process of forming particles
|
EP2186913B1
(de)
|
2003-11-26 |
2016-02-10 |
Celera Corporation |
Mit kardiovaskulären Erkrankungen und dem Ansprechen auf Medikation in Zusammenhang stehende Genpolymorphismen, Methoden zu deren Nachweis und deren Verwendung
|
CN1878602A
(zh)
*
|
2003-11-28 |
2006-12-13 |
三菱化学株式会社 |
有机化合物微粒的制造方法
|
EP1696898B1
(de)
*
|
2003-12-02 |
2015-11-18 |
The Ohio State University Research Foundation |
Zn 2+ chelierende motiv-gebundene kurzkettige fettsäuren als neue klasse von histon-deacetylase-hemmern
|
KR100603974B1
(ko)
|
2003-12-05 |
2006-07-25 |
김갑식 |
고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법
|
ES2584867T3
(es)
*
|
2004-01-12 |
2016-09-29 |
Mannkind Corporation |
Un método que reduce los niveles séricos de proinsulina en diabéticos de tipo 2
|
CA2553973A1
(en)
*
|
2004-01-21 |
2005-08-04 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using aspartyl-protease inihibitors
|
EP1713514B1
(de)
*
|
2004-01-28 |
2021-11-24 |
Johns Hopkins University |
Arzneimittel und genträgerteilchen, die sich schnell durch schleimhautbarrieren bewegen
|
US20050169978A1
(en)
*
|
2004-01-29 |
2005-08-04 |
Shu-Wen Fu |
Wet-micro grinding
|
RU2006130958A
(ru)
*
|
2004-01-29 |
2008-03-10 |
Бакстер Интернэшнл Инк. (Us) |
Наносуспензии антиретровирусных агентов для улучшенной доставки в центральную нервную систему
|
US7692023B2
(en)
*
|
2004-02-11 |
2010-04-06 |
Teva Pharmaceutical Industries Ltd. |
Candesartan cilexetil polymorphs
|
US20050239832A1
(en)
*
|
2004-03-09 |
2005-10-27 |
Varghese John |
Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
|
EP1735293A2
(de)
*
|
2004-03-09 |
2006-12-27 |
Elan Pharmaceuticals, Inc. |
Substituierte hydroxyethylamine als aspartylproteaseinhibitoren
|
WO2005087215A1
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
|
US20060014737A1
(en)
*
|
2004-03-09 |
2006-01-19 |
Varghese John |
Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
|
CA2558034A1
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
US20080090753A1
(en)
*
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
ATE446581T1
(de)
*
|
2004-03-12 |
2009-11-15 |
Trinity College Dublin |
Magnetoresistives medium
|
US20050202051A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Chinea Vanessa I. |
Pharmaceutical vehicle
|
US20050203482A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Chinea Vanessa I. |
Pharmaceutical dispensing apparatus and method
|
EP1729734B1
(de)
*
|
2004-03-30 |
2008-02-27 |
Smithkline Beecham Corporation |
Sprühgetrocknete pharmazeutische zusammensetzungen
|
WO2005094788A1
(ja)
*
|
2004-03-31 |
2005-10-13 |
Toyama Chemical Co., Ltd. |
難溶性薬物の微粒子分散液およびその製造方法
|
AR048650A1
(es)
|
2004-05-04 |
2006-05-10 |
Tibotec Pharm Ltd |
Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
|
MXPA06012702A
(es)
*
|
2004-05-05 |
2007-04-02 |
Teva Pharma |
Preparacion de candesartan cilexetil de alta pureza.
|
JP5236286B2
(ja)
|
2004-05-07 |
2013-07-17 |
セレラ コーポレーション |
肝線維症に関連する遺伝的多型、その検出方法および使用
|
EP2422781A1
(de)
|
2004-05-07 |
2012-02-29 |
Sequoia Pharmaceuticals, Inc. |
Resistenzabweisende retrovirale Proteaseinhibitoren
|
BRPI0511267A
(pt)
|
2004-05-17 |
2007-11-27 |
Tibotec Pharm Ltd |
1,5-diidropirido[3,2-b]indol-2-onas 4-substituìdas
|
US20050252408A1
(en)
|
2004-05-17 |
2005-11-17 |
Richardson H W |
Particulate wood preservative and method for producing same
|
US7316738B2
(en)
*
|
2004-10-08 |
2008-01-08 |
Phibro-Tech, Inc. |
Milled submicron chlorothalonil with narrow particle size distribution, and uses thereof
|
JP2007538050A
(ja)
|
2004-05-17 |
2007-12-27 |
テイボテク・フアーマシユーチカルズ・リミテツド |
抗感染薬剤として有用な6,7,8,9−置換1−フェニル−1,5−ジヒドロ−ピリド[3,2−b]インドール−2−オン
|
AP2006003791A0
(en)
|
2004-05-17 |
2006-10-31 |
Tibotec Pharm Ltd |
1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
|
US20080199493A1
(en)
|
2004-05-25 |
2008-08-21 |
Picker Louis J |
Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
|
US8216610B2
(en)
*
|
2004-05-28 |
2012-07-10 |
Imaginot Pty Ltd. |
Oral paracetamol formulations
|
JP2008500288A
(ja)
*
|
2004-05-28 |
2008-01-10 |
イメイジノット ピーティーワイ エルティーディー |
経口治療用化合物の供給系
|
US8445431B2
(en)
*
|
2004-06-01 |
2013-05-21 |
The Ohio State University |
Ligands having metal binding ability and targeting properties
|
US8012457B2
(en)
|
2004-06-04 |
2011-09-06 |
Acusphere, Inc. |
Ultrasound contrast agent dosage formulation
|
CA2565972A1
(en)
*
|
2004-06-15 |
2005-12-29 |
Baxter International Inc. |
Ex-vivo application of solid microparticulate therapeutic agents
|
US8377948B2
(en)
*
|
2004-06-21 |
2013-02-19 |
The Ohio State University Research Foundation |
Antitumor agents and methods of their use
|
JP2008505929A
(ja)
*
|
2004-07-09 |
2008-02-28 |
エラン ファーマシューティカルズ,インコーポレイテッド |
オキシム誘導体ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
|
WO2006010095A2
(en)
*
|
2004-07-09 |
2006-01-26 |
Elan Pharmaceuticals Inc. |
Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
|
US8409167B2
(en)
|
2004-07-19 |
2013-04-02 |
Broncus Medical Inc |
Devices for delivering substances through an extra-anatomic opening created in an airway
|
CA2574767C
(en)
|
2004-07-19 |
2015-02-17 |
Celator Pharmaceuticals, Inc. |
Particulate constructs for release of active agents
|
MX2007001929A
(es)
*
|
2004-08-18 |
2007-04-17 |
Concordia Pharmaceuticals Inc |
Metodos y composiciones para suministro oral de acido farnesiltiosalicilico (fts).
|
CA2577583A1
(en)
*
|
2004-08-19 |
2006-03-02 |
Alza Corporation |
Controlled release nanoparticle active agent formulation dosage forms and methods
|
DK1786784T3
(da)
|
2004-08-20 |
2011-02-14 |
Mannkind Corp |
Katalyse af diketopiperazinsyntese
|
PL2322180T3
(pl)
|
2004-08-23 |
2015-10-30 |
Mannkind Corp |
Sole diketopiperazyny do dostarczania leków
|
GB0418791D0
(en)
*
|
2004-08-23 |
2004-09-22 |
Glaxo Group Ltd |
Novel process
|
EP1802574A2
(de)
*
|
2004-08-27 |
2007-07-04 |
Elan Pharmaceuticals Inc. |
Verfahren zur behandlung von amyloidose mit ethanolcyclicaminderivat-aspartylproteasehemmern
|
JP2008511637A
(ja)
|
2004-08-27 |
2008-04-17 |
ザ ダウ ケミカル カンパニー |
致命的な感染症を治療する薬剤組成物の増強された供給
|
WO2006028074A1
(ja)
*
|
2004-09-07 |
2006-03-16 |
Mitsubishi Chemical Corporation |
微粒子化された物質の製造方法および微粒子化された物質
|
US20080171687A1
(en)
*
|
2004-09-16 |
2008-07-17 |
Abraxis Bioscience, Inc. |
Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
|
WO2006035418A2
(en)
*
|
2004-09-27 |
2006-04-06 |
Sigmoid Biotechnologies Limited |
Microcapsules comprising a methylxanthine and a corticosteroid
|
US7426948B2
(en)
*
|
2004-10-08 |
2008-09-23 |
Phibrowood, Llc |
Milled submicron organic biocides with narrow particle size distribution, and uses thereof
|
US20060112850A1
(en)
|
2004-10-14 |
2006-06-01 |
Jun Zhang |
Micronized wood preservative formulations in organic carriers
|
KR100651728B1
(ko)
*
|
2004-11-10 |
2006-12-06 |
한국전자통신연구원 |
정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
|
WO2006050926A2
(en)
*
|
2004-11-12 |
2006-05-18 |
Idea Ag |
Extended surface aggregates in the treatment of skin conditions
|
US20090155331A1
(en)
*
|
2005-11-16 |
2009-06-18 |
Elan Pharma International Limited |
Injectable nanoparticulate olanzapine formulations
|
CN101106972A
(zh)
*
|
2004-11-16 |
2008-01-16 |
伊兰制药国际有限公司 |
注射用纳米微粒奥氮平制剂
|
WO2006121468A1
(en)
*
|
2004-11-22 |
2006-11-16 |
Genelabs Technologies, Inc. |
5-nitro-nucleoside compounds for treating viral infections
|
UA89513C2
(uk)
*
|
2004-12-03 |
2010-02-10 |
Элан Фарма Интернешнл Лтд. |
Стабільна композиція з наночастинок ралоксифену гідрохлориду
|
EP1839502A4
(de)
*
|
2004-12-07 |
2010-03-24 |
Ajinomoto Kk |
Feines aminosäurepulver und suspension davon
|
US20080145430A1
(en)
*
|
2004-12-08 |
2008-06-19 |
Santipharp Panmai |
Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
|
KR20070116581A
(ko)
*
|
2004-12-15 |
2007-12-10 |
엘란 파마 인터내셔널 리미티드 |
나노입자형 타크롤리무스 제제
|
US20110177306A1
(en)
*
|
2004-12-17 |
2011-07-21 |
Mitsubishi Chemical Corporation |
Novel Core-Shell Structure
|
WO2006069098A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Elan Pharma International Ltd. |
Nanoparticulate bicalutamide formulations
|
CA2858733C
(en)
*
|
2004-12-31 |
2017-12-19 |
Iceutica Pty Ltd |
Nanoparticle compositions and methods for synthesis thereof
|
AU2005321751B2
(en)
*
|
2004-12-31 |
2012-04-05 |
Iceutica Pty Ltd |
Nanoparticle composition and methods for synthesis thereof
|
AU2012201630B8
(en)
*
|
2004-12-31 |
2014-03-06 |
Iceutica Pty Ltd |
NanoParticle Composition(s) and Method for Synthesis Thereof
|
WO2006074218A2
(en)
*
|
2005-01-06 |
2006-07-13 |
Elan Pharma International Ltd. |
Nanoparticulate candesartan formulations
|
WO2006073154A1
(ja)
*
|
2005-01-07 |
2006-07-13 |
Eisai R&D Management Co., Ltd. |
医薬組成物及びその製造方法
|
WO2006087919A1
(ja)
*
|
2005-01-28 |
2006-08-24 |
Takeda Pharmaceutical Company Limited |
難水溶性物質含有微細化組成物
|
ES2265262B1
(es)
*
|
2005-01-31 |
2008-03-01 |
Activery Biotech, S.L.(Titular Al 50%) |
Procedimiento para la obtencion de sistemas micro- y nanodispersos.
|
RU2423378C2
(ru)
|
2005-02-08 |
2011-07-10 |
Рисерч Дивелопмент Фаундейшн |
Композиции и способы, связанные с растворимыми сопряженными с g-белком рецепторами (sgpcr)
|
KR20070112164A
(ko)
|
2005-02-15 |
2007-11-22 |
엘란 파마 인터내셔널 리미티드 |
나노입자형 벤조디아제핀의 에어로졸과 주사가능한 제제
|
CN101128474A
(zh)
*
|
2005-02-28 |
2008-02-20 |
健亚生物科技公司 |
用于治疗病毒感染的三环核苷前药
|
AU2005100176A4
(en)
*
|
2005-03-01 |
2005-04-07 |
Gym Tv Pty Ltd |
Garbage bin clip
|
US20080254114A1
(en)
*
|
2005-03-03 |
2008-10-16 |
Elan Corporation Plc |
Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
|
US20060204588A1
(en)
*
|
2005-03-10 |
2006-09-14 |
Elan Pharma International Limited |
Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
|
WO2006099365A2
(en)
|
2005-03-11 |
2006-09-21 |
Applera Corporation |
Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
|
JP2008533174A
(ja)
*
|
2005-03-16 |
2008-08-21 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子ロイコトリエン受容体拮抗薬/副腎皮質ステロイド製剤
|
MX2007011495A
(es)
*
|
2005-03-17 |
2007-12-06 |
Elan Pharma Int Ltd |
Composiciones de bifosfonato en nanoparticulas.
|
EA200702049A1
(ru)
*
|
2005-03-23 |
2008-02-28 |
Элан Фарма Интернэшнл Лтд. |
Композиции наночастиц кортикостероидов с антигистаминами
|
US20070224282A1
(en)
*
|
2005-03-28 |
2007-09-27 |
Toyama Chemical Co., Ltd. |
Fine Dispersion of Sparingly Soluble Drug and Process for Producing the Same
|
EP2392347A3
(de)
|
2005-03-31 |
2012-01-18 |
GlaxoSmithKline Biologicals S.A. |
Impfstoffe gegen Chlamydieninfektion
|
TW200710091A
(en)
|
2005-04-11 |
2007-03-16 |
Tibotec Pharm Ltd |
(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
|
US20060246141A1
(en)
*
|
2005-04-12 |
2006-11-02 |
Elan Pharma International, Limited |
Nanoparticulate lipase inhibitor formulations
|
CA2603084A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising cyclosporine
|
CA2604735A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Nanoparticulate quinazoline derivative formulations
|
US20090252807A1
(en)
*
|
2005-04-13 |
2009-10-08 |
Elan Pharma International Limited |
Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives
|
WO2006108637A2
(de)
*
|
2005-04-13 |
2006-10-19 |
Abbott Gmbh & Co.Kg |
Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
|
MX2007012103A
(es)
*
|
2005-04-13 |
2007-11-20 |
Pfizer Prod Inc |
Formulaciones deposito inyectables y metodos para proporcionar una liberacion sostenida de composiciones de nanoparticulas.
|
US20080305161A1
(en)
*
|
2005-04-13 |
2008-12-11 |
Pfizer Inc |
Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
|
ITMI20050739A1
(it)
*
|
2005-04-22 |
2006-10-23 |
Effebi Spa |
Piastrina di connsessione valvola-attuatore
|
WO2006116557A1
(en)
*
|
2005-04-25 |
2006-11-02 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
JP5164830B2
(ja)
|
2005-04-29 |
2013-03-21 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
結核菌感染の予防または治療のための新規方法
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
JP2008540550A
(ja)
*
|
2005-05-10 |
2008-11-20 |
エラン・ファルマ・インターナショナル・リミテッド |
ビタミンk2を含むナノ粒子および制御放出組成物
|
CA2607494A1
(en)
*
|
2005-05-10 |
2007-08-02 |
Elan Pharma International Limited |
Nanoparticulate clopidogrel formulations
|
WO2006132752A1
(en)
*
|
2005-05-10 |
2006-12-14 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising vitamin k2
|
EP1763525A2
(de)
*
|
2005-05-10 |
2007-03-21 |
Teva Pharmaceutical Industries Ltd. |
Stabiles mikronisiertes candesartan-cilexetil und herstellungsverfahren
|
EP1915139A1
(de)
*
|
2005-05-16 |
2008-04-30 |
Elan Pharma International Limited |
Nanoteilchenförmige und kontrolliert freigesetzte zusammensetzungen mit einem cephalosporin
|
EA200702595A1
(ru)
*
|
2005-05-23 |
2008-12-30 |
Элан Фарма Интернэшнл Лимитед |
Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитов
|
EP1895984B8
(de)
|
2005-06-03 |
2010-05-12 |
Elan Pharma International Limited |
Nanoteilchenförmige imatinib-mesylat-formulierungen
|
CA2610480A1
(en)
*
|
2005-06-03 |
2007-05-10 |
Scott Jenkins |
Nanoparticulate acetaminophen formulations
|
WO2006133045A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Elan Pharma International, Limited |
Nanoparticulate benidipine compositions
|
EP1888120B1
(de)
*
|
2005-06-07 |
2012-12-05 |
Ramot at Tel Aviv University Ltd. |
Neue salze von konjugierten psychotropen arzneimitteln und verfahren zu ihrer herstellung
|
JP2009517485A
(ja)
*
|
2005-06-08 |
2009-04-30 |
エラン・ファルマ・インターナショナル・リミテッド |
セフジトレンを含むナノ粒子状および制御放出組成物
|
EP1898882B1
(de)
*
|
2005-06-09 |
2009-10-28 |
Elan Pharma International Limited |
Nanopartikuläre ebastinformulierungen
|
BRPI0611626A2
(pt)
*
|
2005-06-13 |
2010-09-21 |
Elan Pharma Int Ltd |
formulações da combinação de nanopartìculas de clopidogrel e aspirina
|
EP1931340A2
(de)
*
|
2005-06-15 |
2008-06-18 |
Elan Pharma International Limited |
Nanopartikuläre azelnidipin-formulierungen
|
CA2613474A1
(en)
*
|
2005-06-20 |
2007-03-08 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
|
CN101242810A
(zh)
*
|
2005-06-22 |
2008-08-13 |
伊兰制药国际有限公司 |
纳米颗粒甲地孕酮制剂
|
CA2613261A1
(en)
*
|
2005-06-24 |
2006-12-28 |
Genelabs Technologies, Inc. |
Heteroaryl derivatives for treating viruses
|
WO2007000842A1
(ja)
*
|
2005-06-29 |
2007-01-04 |
Mitsubishi Chemical Corporation |
粒状物分散組成物及びその製造方法、並びに、粒状物及び医薬品
|
CN101212964A
(zh)
*
|
2005-06-29 |
2008-07-02 |
帝斯曼知识产权资产管理有限公司 |
异黄酮纳米颗粒及其用途
|
CA2614409C
(en)
*
|
2005-07-07 |
2014-05-20 |
Nanotherapeutics, Inc |
Process for milling and preparing powders and compositions produced thereby
|
US20070298109A1
(en)
*
|
2005-07-07 |
2007-12-27 |
The Trustees Of The University Of Pennsylvania |
Nano-scale devices
|
EP1904041A2
(de)
*
|
2005-07-07 |
2008-04-02 |
Elan Pharma International Limited |
Nanopartikuläre clarithromycinformulierung
|
AU2006269961B2
(en)
*
|
2005-07-15 |
2012-07-19 |
Map Pharmaceuticals, Inc. |
Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
EP1915134A2
(de)
*
|
2005-08-10 |
2008-04-30 |
Novartis AG |
Formulierungen von 7-(t-butoxy)iminomethylcamptothecin
|
PE20070232A1
(es)
*
|
2005-08-10 |
2007-04-09 |
Novartis Ag |
Composicion que comprende microparticulas de 7-terbutoxi-imino-metil-campotecina
|
EP1915131A4
(de)
*
|
2005-08-12 |
2012-07-25 |
Astrazeneca Ab |
Verfahren
|
GB0516549D0
(en)
*
|
2005-08-12 |
2005-09-21 |
Sulaiman Brian |
Milling system
|
SI3311805T1
(sl)
|
2005-08-31 |
2020-07-31 |
Abraxis Bioscience, Llc |
Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva
|
EP1928435B8
(de)
*
|
2005-08-31 |
2019-03-20 |
Abraxis BioScience, LLC |
Zusammensetzungen von schwer wasserlöslichen arzneimitteln mit erhöhter stabilität und verfahren zu deren herstellung
|
JPWO2007029660A1
(ja)
*
|
2005-09-06 |
2009-03-19 |
アステラス製薬株式会社 |
腸溶性基剤が表面に吸着した難溶性薬物の微小粒子
|
CA2622200A1
(en)
*
|
2005-09-13 |
2007-03-22 |
Elan Pharma International, Limited |
Nanoparticulate tadalafil formulations
|
CN104324366B
(zh)
|
2005-09-14 |
2016-10-05 |
曼金德公司 |
以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
|
EP1933814A2
(de)
*
|
2005-09-15 |
2008-06-25 |
Elan Pharma International Limited |
Nanoteilchenförmige aripiprazol-formulierungen
|
US7799530B2
(en)
|
2005-09-23 |
2010-09-21 |
Celera Corporation |
Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
|
US8084420B2
(en)
*
|
2005-09-29 |
2011-12-27 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
WO2007041481A1
(en)
*
|
2005-09-29 |
2007-04-12 |
Biodel, Inc. |
Rapid acting and prolonged acting insulin preparations
|
US7713929B2
(en)
|
2006-04-12 |
2010-05-11 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
US20070077309A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Wong Patrick S |
Banded controlled release nanoparticle active agent formulation dosage forms and methods
|
WO2007044813A1
(en)
|
2005-10-07 |
2007-04-19 |
Exelixis, Inc. |
PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
|
BRPI0617162B8
(pt)
|
2005-10-07 |
2021-05-25 |
Exelixis Inc |
compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
|
WO2007047305A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
|
WO2007047306A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
|
US7695911B2
(en)
|
2005-10-26 |
2010-04-13 |
Celera Corporation |
Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
|
DE102005053862A1
(de)
*
|
2005-11-04 |
2007-05-10 |
Pharmasol Gmbh |
Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
|
RU2448703C2
(ru)
|
2005-11-23 |
2012-04-27 |
Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем |
Онкогенное ras-специфичное цитотоксическое соединение и способы его применения
|
KR101405545B1
(ko)
|
2005-11-28 |
2014-07-03 |
마리누스 파마슈티컬스 |
ganaxolone 제형, 이의 제조방법 및 용도
|
EP3263117A1
(de)
*
|
2005-11-28 |
2018-01-03 |
Imaginot Pty Ltd. |
Abgabesystem für eine orale therapeutische verbindung
|
JP2009518300A
(ja)
*
|
2005-12-02 |
2009-05-07 |
エラン ファーマ インターナショナル リミテッド |
モメタゾン組成物ならびにその作製方法および使用方法
|
TW200730478A
(en)
*
|
2005-12-12 |
2007-08-16 |
Genelabs Tech Inc |
N-(6-membered aromatic ring)-amido anti-viral compounds
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
CA2635531C
(en)
|
2005-12-29 |
2014-06-17 |
Lexicon Pharmaceutical Inc. |
Multicyclic amino acid derivatives and methods of their use
|
AU2007239095B2
(en)
|
2006-01-09 |
2012-05-03 |
The Regents Of The University Of California |
Immunostimulatory combinations for vaccine adjuvants
|
WO2007095342A2
(en)
*
|
2006-02-15 |
2007-08-23 |
Tika Läkemedel Ab |
Stable corticosteroid mixtures
|
MX360812B
(es)
|
2006-02-22 |
2018-11-16 |
Mannkind Corp |
Un método para mejorar las propiedades farmacéuticas de micropartículas que contienen dicetopiperazina y un agente activo.
|
JP2009527504A
(ja)
*
|
2006-02-23 |
2009-07-30 |
イオメディックス スリープ インターナショナル エスアールエル |
良質な睡眠の誘導および維持のための組成物および方法
|
US7649098B2
(en)
|
2006-02-24 |
2010-01-19 |
Lexicon Pharmaceuticals, Inc. |
Imidazole-based compounds, compositions comprising them and methods of their use
|
US8367112B2
(en)
*
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
US20090099175A1
(en)
*
|
2006-03-01 |
2009-04-16 |
Arrington Mark P |
Phosphodiesterase 10 inhibitors
|
US11311477B2
(en)
|
2006-03-07 |
2022-04-26 |
Sgn Nanopharma Inc. |
Ophthalmic preparations
|
US10137083B2
(en)
|
2006-03-07 |
2018-11-27 |
SGN Nanopharma Inc |
Ophthalmic preparations
|
EP2001439A2
(de)
*
|
2006-03-07 |
2008-12-17 |
Novavax, Inc. |
Nanoemulsionen von schlecht löslichen pharmazeutischen aktivbestandteilen und herstellungsverfahren dafür
|
CN101453986A
(zh)
*
|
2006-03-14 |
2009-06-10 |
默克公司 |
通过微研磨和在微晶种上结晶生产结晶有机微粒组合物的方法和设备及其应用
|
AU2007233683A1
(en)
|
2006-04-03 |
2007-10-11 |
Janssen R&D Ireland |
HIV inhibiting 3,4-dihydro-imidazo[4,5-b]pyridin-5-ones
|
AU2007238114B2
(en)
*
|
2006-04-12 |
2010-10-14 |
Biodel, Inc. |
Rapid acting and long acting insulin combination formulations
|
WO2008054508A2
(en)
*
|
2006-04-13 |
2008-05-08 |
Alza Corporation |
Stable nanosized amorphous drug
|
RS56600B1
(sr)
|
2006-04-19 |
2018-02-28 |
Novartis Ag |
6-o-supstituisana jedinjenja benzoksazola i benzotiazola i postupci inhibicije csf-1r signalinga
|
JP2007306950A
(ja)
|
2006-05-15 |
2007-11-29 |
Osaka Univ |
薬効成分ナノ粒子分散液の製造方法
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
BRPI0712130A2
(pt)
*
|
2006-05-30 |
2012-01-17 |
Elan Pharma Int Ltd |
formulações de posaconazol em nanopartìculas
|
CA2655056C
(en)
*
|
2006-06-12 |
2016-04-12 |
Smith & Nephew, Inc. |
Systems, methods and devices for tibial resection
|
KR101403135B1
(ko)
*
|
2006-06-14 |
2014-06-19 |
인터벳 인터내셔널 비.브이. |
벤지미다졸 카르바메이트 및 폴리솔베이트를 포함하는 현탁물
|
PT2040671T
(pt)
|
2006-06-23 |
2018-03-14 |
Janssen Sciences Ireland Uc |
Suspensões aquosas de tmc278
|
WO2008002485A2
(en)
*
|
2006-06-23 |
2008-01-03 |
Alza Corporation |
Increased amorphous stability of poorly water soluble drugs by nanosizing
|
US20080050450A1
(en)
*
|
2006-06-26 |
2008-02-28 |
Mutual Pharmaceutical Company, Inc. |
Active Agent Formulations, Methods of Making, and Methods of Use
|
SI2041088T1
(sl)
|
2006-06-28 |
2014-05-30 |
Amgen Inc. |
Inhibitorji transporter-1 glicina
|
NZ599069A
(en)
*
|
2006-06-30 |
2013-10-25 |
Iceutica Pty Ltd |
Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form
|
AU2007264418B2
(en)
*
|
2006-06-30 |
2012-05-03 |
Iceutica Pty Ltd |
Methods for the preparation of biologically active compounds in nanoparticulate form
|
US20080213374A1
(en)
*
|
2006-07-10 |
2008-09-04 |
Elan Pharma International Limited |
Nanoparticulate sorafenib formulations
|
JP5192485B2
(ja)
*
|
2006-07-17 |
2013-05-08 |
ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド |
向精神性薬物またはgabaアゴニストと有機酸とを含むコンジュゲート、ならびに疼痛および他のcns障害を治療するためのそれらの使用
|
AR062827A1
(es)
*
|
2006-07-20 |
2008-12-10 |
Genelabs Tech Inc |
Inhibidores virales policiclicos, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de una infeccion viral mediada porl el virus de la hepatitis c
|
WO2008013416A1
(en)
*
|
2006-07-27 |
2008-01-31 |
Amorepacific Corporation |
Process for preparing powder comprising nanoparticles of sparingly soluble drug
|
DK2420494T3
(en)
|
2006-08-16 |
2015-01-12 |
J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone |
Use of thiadiazole compounds as inhibitors of kynurenine 3-monooxygenase
|
DK2054397T3
(en)
|
2006-08-16 |
2016-01-18 |
J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone |
SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
|
EP2057151A4
(de)
*
|
2006-08-28 |
2010-07-21 |
Hetero Drugs Ltd |
Verfahren zur reinigung von aprepitant
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
AU2007292902B8
(en)
*
|
2006-09-08 |
2013-09-05 |
Johns Hopkins University |
Compositions and methods for enhancing transport through mucus
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US8414926B1
(en)
|
2006-09-12 |
2013-04-09 |
University Of South Florida |
Nanoparticles with covalently bound surfactant for drug delivery
|
US8080645B2
(en)
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US20110021592A1
(en)
*
|
2006-09-14 |
2011-01-27 |
Shlomo Magdassi |
Organic nanoparticles obtained from microemulsions by solvent evaporation
|
AR063704A1
(es)
*
|
2006-09-14 |
2009-02-11 |
Makhteshim Chem Works Ltd |
Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
|
CL2007002689A1
(es)
|
2006-09-18 |
2008-04-18 |
Vitae Pharmaceuticals Inc |
Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
|
EP2081548A2
(de)
*
|
2006-09-22 |
2009-07-29 |
Labopharm Inc. |
Zusammensetzungen und verfahren für die ph-gezielte arzneiabgabe
|
CA2915679C
(en)
|
2006-10-20 |
2017-12-12 |
Celera Corporation |
Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
|
CN1946120B
(zh)
*
|
2006-10-20 |
2010-05-12 |
华为技术有限公司 |
实现话单关联的方法及系统
|
US8946200B2
(en)
*
|
2006-11-02 |
2015-02-03 |
Southwest Research Institute |
Pharmaceutically active nanosuspensions
|
US20100036091A1
(en)
*
|
2006-11-10 |
2010-02-11 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
WO2008133722A2
(en)
*
|
2006-11-10 |
2008-11-06 |
Ucb Pharma S.A. |
Anti human sclerostin antibodies
|
CA2669392C
(en)
*
|
2006-11-17 |
2016-05-10 |
Abbott Gmbh & Co. Kg |
Nanocrystals for use in topical cosmetic formulations and method of production thereof
|
KR20080047957A
(ko)
*
|
2006-11-27 |
2008-05-30 |
주식회사 엠디바이오알파 |
고혈압의 치료 및 예방을 위한 약제 조성물
|
AU2007325628A1
(en)
|
2006-11-28 |
2008-06-05 |
Marinus Pharmaceuticals |
Nanoparticulate formulations and methods for the making and use thereof
|
US20080292695A1
(en)
*
|
2006-12-01 |
2008-11-27 |
Kristin Arnold |
Carvedilol forms, compositions, and methods of preparation thereof
|
US20090028935A1
(en)
*
|
2006-12-01 |
2009-01-29 |
Kristin Arnold |
Carvedilol forms, compositions, and methods of preparation thereof
|
US20080138405A1
(en)
*
|
2006-12-06 |
2008-06-12 |
Raheja Praveen |
Sirolimus nanodispersion
|
UA99270C2
(en)
|
2006-12-12 |
2012-08-10 |
Лексикон Фармасьютикалз, Инк. |
4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
|
EP2104489A2
(de)
*
|
2006-12-26 |
2009-09-30 |
FemmePharma Holding Company, Inc. |
Topische verabreichung von danazol
|
DE102007001473A1
(de)
|
2007-01-08 |
2008-07-10 |
Andreas Lemke |
Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck
|
TW200848039A
(en)
*
|
2007-02-09 |
2008-12-16 |
Astrazeneca Ab |
Pharmaceutical compositions
|
WO2008097165A1
(en)
*
|
2007-02-09 |
2008-08-14 |
Astrazeneca Ab |
Process for preparation of a stable dispersion of solid amorphous submicron particles in an aqueous medium
|
HUE026884T2
(en)
|
2007-02-11 |
2016-08-29 |
Map Pharmaceuticals Inc |
DHE is a therapeutic method of administration for the rapid relief of migraine while minimizing side effects
|
US20100151035A1
(en)
*
|
2007-03-13 |
2010-06-17 |
Sandoz Ag |
Pharmaceutical compositions of poorly soluble drugs
|
CN101679308B
(zh)
|
2007-03-14 |
2014-05-07 |
埃克塞里艾克西斯公司 |
Hedgehog途径抑制剂
|
CL2008000746A1
(es)
|
2007-03-14 |
2008-09-22 |
Tibotec Pharm Ltd |
Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
|
WO2008124522A2
(en)
*
|
2007-04-04 |
2008-10-16 |
Biodel, Inc. |
Amylin formulations
|
WO2008122965A2
(en)
|
2007-04-04 |
2008-10-16 |
Sigmoid Pharma Limited |
Pharmaceutical cyclosporin compositions
|
TWI405590B
(zh)
|
2007-04-06 |
2013-08-21 |
Activus Pharma Co Ltd |
微粉碎化有機化合物粒子之製法
|
LT2191001T
(lt)
|
2007-04-09 |
2016-10-10 |
University Of Florida Research Foundation, Inc. |
Raav vektoriaus kompozicijos, turinčios tirozin-modifikuotų kapsidės baltymų ir jų panaudojimo būdai
|
CA2685118C
(en)
*
|
2007-04-26 |
2016-11-01 |
Sigmoid Pharma Limited |
Manufacture of multiple minicapsules
|
EP2073798A2
(de)
*
|
2007-05-01 |
2009-07-01 |
Sigmoid Pharma Limited |
Pharmazeutische nimodipin-zusammensetzungen
|
US8703204B2
(en)
|
2007-05-03 |
2014-04-22 |
Bend Research, Inc. |
Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
|
WO2008135828A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a drug, ethylcellulose, and a bile salt
|
WO2008137960A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Questor Pharmaceuticals, Inc. |
Nasal administration of benzodiazepines
|
US8530463B2
(en)
*
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
WO2008144062A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
Csf-1r inhibitors, compositions, and methods of use
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
JP5596540B2
(ja)
*
|
2007-05-31 |
2014-09-24 |
ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド |
安定な機能性ナノ粒子を形成する方法
|
WO2008149230A2
(en)
|
2007-06-04 |
2008-12-11 |
Pfizer Products Inc. |
Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
|
EP2162120B1
(de)
|
2007-06-04 |
2016-05-04 |
Bend Research, Inc |
Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
|
WO2009006479A2
(en)
|
2007-07-02 |
2009-01-08 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
US8623415B2
(en)
|
2007-07-06 |
2014-01-07 |
M. Technique Co., Ltd. |
Method for producing biologically ingestible microparticles, biologically ingestible microparticles, and dispersion and pharmaceutical composition containing the same
|
ES2437331T3
(es)
|
2007-07-12 |
2014-01-10 |
Janssen R&D Ireland |
Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
|
EP2178519B1
(de)
|
2007-07-13 |
2012-04-25 |
Bend Research, Inc. |
Nanopartikel mit einem nicht ionisierbaren Polymer und einem anionischen Zellulosepolymer
|
EP2187883A2
(de)
*
|
2007-08-10 |
2010-05-26 |
Genelabs Technologies, Inc. |
Stickstoffhaltige bicyclische chemische entitäten zur behandlung von virusinfektionen
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
RU2468034C2
(ru)
|
2007-08-27 |
2012-11-27 |
ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи |
Иммуногенные композиции и способы
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
WO2009029729A1
(en)
*
|
2007-08-31 |
2009-03-05 |
Genelabs Technologies, Inc. |
Amino tricyclic-nucleoside compounds, compositions, and methods of use
|
AU2008296971B2
(en)
*
|
2007-09-03 |
2014-10-02 |
Nanoshift, Llc |
Particulate compositions for delivery of poorly soluble drugs
|
US20090130210A1
(en)
*
|
2007-09-11 |
2009-05-21 |
Raheja Praveen |
Pharmaceutical compositions of sirolimus
|
US20090068266A1
(en)
*
|
2007-09-11 |
2009-03-12 |
Raheja Praveen |
Sirolimus having specific particle size and pharmaceutical compositions thereof
|
WO2009035558A1
(en)
*
|
2007-09-12 |
2009-03-19 |
Merck & Co., Inc. |
Process for the production of a crystalline glucagon receptor antagonist compound
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
DK2200588T3
(da)
*
|
2007-09-25 |
2019-07-01 |
Solubest Ltd |
Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
EP2535428B1
(de)
|
2007-10-01 |
2015-09-09 |
Longhorn Vaccines and Diagnostics, LLC |
System zum Sammeln und Transportieren biologischer Proben sowie Verfahren zu seiner Verwendung
|
WO2009048251A2
(en)
*
|
2007-10-11 |
2009-04-16 |
Mazence Inc. |
Pharmaceutical composition containing micronized particles of naphthoquinone-based compound
|
CA2702261A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Map Pharmaceuticals, Inc. |
Inhalation drug delivery
|
US9206233B2
(en)
|
2007-10-19 |
2015-12-08 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Templates for controlling synthesis of nanoparticles into discrete assemblies
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
US8642062B2
(en)
|
2007-10-31 |
2014-02-04 |
Abbott Cardiovascular Systems Inc. |
Implantable device having a slow dissolving polymer
|
US8039212B2
(en)
|
2007-11-05 |
2011-10-18 |
Celera Corporation |
Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
|
JP2011503232A
(ja)
|
2007-11-20 |
2011-01-27 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
免疫応答の調節
|
US8598165B2
(en)
|
2007-11-26 |
2013-12-03 |
University Of Kansas |
Morpholines as selective inhibitors of cytochrome P450 2A13
|
EP2224923A4
(de)
|
2007-11-28 |
2013-05-15 |
Sequoia Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur hemmung von zytochrom p450 2d6
|
EP2231169B1
(de)
|
2007-12-06 |
2016-05-04 |
Bend Research, Inc. |
Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
|
EP2240162A4
(de)
|
2007-12-06 |
2013-10-09 |
Bend Res Inc |
Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
|
KR100961880B1
(ko)
*
|
2007-12-12 |
2010-06-09 |
중앙대학교 산학협력단 |
밀링에 의한 기능성 약물나노입자의 제조방법 및 상기제조방법에 의해 입자 표면이 개질된 약물나노입자 제제
|
US20090238867A1
(en)
*
|
2007-12-13 |
2009-09-24 |
Scott Jenkins |
Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
|
JP2011506483A
(ja)
*
|
2007-12-14 |
2011-03-03 |
アムジエン・インコーポレーテツド |
抗スクレロスチン抗体を用いた骨折の治療方法
|
ES2437595T3
(es)
|
2007-12-20 |
2014-01-13 |
Novartis Ag |
Derivados de tiazol usados como inhibidores de la PI 3 quinasa
|
EP2231668A1
(de)
*
|
2007-12-21 |
2010-09-29 |
GlaxoSmithKline LLC |
Kondensierte pentacyclische derivate zur verwendung bei der behandlung von flaviviridae-infektionen
|
US9242295B2
(en)
|
2007-12-21 |
2016-01-26 |
The Univeristy Of Texas At Arlington |
Bulk nanocomposite magnets and methods of making bulk nanocomposite magnets
|
US20100054981A1
(en)
*
|
2007-12-21 |
2010-03-04 |
Board Of Regents, The University Of Texas System |
Magnetic nanoparticles, bulk nanocomposite magnets, and production thereof
|
KR101405823B1
(ko)
*
|
2007-12-24 |
2014-06-12 |
주식회사 케이티앤지생명과학 |
녹내장의 치료 및 예방을 위한 약제 조성물
|
KR20090071829A
(ko)
*
|
2007-12-28 |
2009-07-02 |
주식회사 머젠스 |
신장질환의 치료 및 예방을 위한 약제 조성물
|
US20090175840A1
(en)
*
|
2008-01-04 |
2009-07-09 |
Biodel, Inc. |
Insulin formulations for insulin release as a function of tissue glucose levels
|
IL188647A0
(en)
*
|
2008-01-08 |
2008-11-03 |
Orina Gribova |
Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
|
US20090202649A1
(en)
*
|
2008-02-06 |
2009-08-13 |
Subhash Gore |
Fenofibrate formulations
|
US8207369B2
(en)
|
2008-02-11 |
2012-06-26 |
Ramot At Tel-Aviv University Ltd. |
Conjugates for treating neurodegenerative diseases and disorders
|
US20090221620A1
(en)
|
2008-02-20 |
2009-09-03 |
Celera Corporation |
Gentic polymorphisms associated with stroke, methods of detection and uses thereof
|
EP2257160B1
(de)
|
2008-02-21 |
2017-07-05 |
Sequoia Pharmaceuticals, Inc. |
Diamidhemmer von cytochrom p450
|
US20110009362A1
(en)
*
|
2008-02-27 |
2011-01-13 |
Dr. Reddy's Laboratories Ltd. |
Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof
|
CN101965195A
(zh)
|
2008-03-05 |
2011-02-02 |
巴克斯特国际公司 |
用于药物投送的组合物和方法
|
US8404850B2
(en)
*
|
2008-03-13 |
2013-03-26 |
Southwest Research Institute |
Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
|
KR20110007095A
(ko)
*
|
2008-03-21 |
2011-01-21 |
엘란 파마 인터내셔널 리미티드 |
이마티니브의 부위-특이적 전달을 위한 조성물 및 사용방법
|
US20090258865A1
(en)
*
|
2008-03-28 |
2009-10-15 |
Hale Biopharma Ventures, Llc |
Administration of benzodiazepine compositions
|
HU230862B1
(hu)
*
|
2008-04-28 |
2018-10-29 |
DARHOLDING Vagyonkezelő Kft |
Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
|
EP2285352A2
(de)
*
|
2008-05-13 |
2011-02-23 |
Dr. Reddy's Laboratories Ltd. |
Atorvastatin-zusammensetzungen
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
DE202009018480U1
(de)
|
2008-06-13 |
2012-01-26 |
Mannkind Corp. |
Trockenpulverinhalator und System zur Medikamentenabgabe
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
GB2460915B
(en)
*
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
|
MX2010014240A
(es)
|
2008-06-20 |
2011-03-25 |
Mankind Corp |
Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
|
EP2733222A1
(de)
|
2008-07-09 |
2014-05-21 |
Celera Corporation |
Mit kardiovaskulären Krankheiten assoziierte, genetische Polymorphismen, Verfahren zum Nachweis und Verwendungen davon
|
US20100151037A1
(en)
*
|
2008-08-07 |
2010-06-17 |
Yivan Jiang |
Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
|
DE102008037025C5
(de)
|
2008-08-08 |
2016-07-07 |
Jesalis Pharma Gmbh |
Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
|
TWI532497B
(zh)
|
2008-08-11 |
2016-05-11 |
曼凱公司 |
超快起作用胰島素之用途
|
US8722706B2
(en)
*
|
2008-08-15 |
2014-05-13 |
Southwest Research Institute |
Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
|
US8148414B2
(en)
|
2008-08-19 |
2012-04-03 |
Xenoport, Inc. |
Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
|
US9700525B2
(en)
|
2008-08-20 |
2017-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College |
Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders
|
CA2749941C
(en)
|
2008-09-10 |
2018-04-24 |
Biochemics, Inc. |
Ibuprofen for topical administration
|
JP5536654B2
(ja)
*
|
2008-09-19 |
2014-07-02 |
株式会社アクティバスファーマ |
医療用複合有機化合物粉体、その製造方法ならびに懸濁液
|
TWI580441B
(zh)
*
|
2008-09-19 |
2017-05-01 |
愛爾康研究有限公司 |
穩定的藥學次微米懸浮液及其形成方法
|
GB0818403D0
(en)
*
|
2008-10-08 |
2008-11-12 |
Univ Leuven Kath |
Aqueous electrophoretic deposition
|
US8309134B2
(en)
*
|
2008-10-03 |
2012-11-13 |
Southwest Research Institute |
Modified calcium phosphate nanoparticle formation
|
EP2334845A2
(de)
*
|
2008-10-06 |
2011-06-22 |
Katholieke Universiteit Leuven K.U. Leuven R&D |
Funktionelle schichten von biomolekülen und lebenden zellen und neues system zu ihrer herstellung
|
US20100098770A1
(en)
*
|
2008-10-16 |
2010-04-22 |
Manikandan Ramalingam |
Sirolimus pharmaceutical formulations
|
US8277697B2
(en)
*
|
2008-10-29 |
2012-10-02 |
Global Oled Technology Llc |
Color filter element with improved colorant dispersion
|
US20100160369A1
(en)
|
2008-12-04 |
2010-06-24 |
Exelixis, Inc. |
S1P1 Agonists and Methods of Making And Using
|
EP2376068A2
(de)
*
|
2008-12-15 |
2011-10-19 |
Banner Pharmacaps, Inc. |
Verfahren zur verbesserung der freisetzung und absorption von wasserunl?slichen wirkstoffen
|
JP2012512255A
(ja)
|
2008-12-17 |
2012-05-31 |
アムジエン・インコーポレーテツド |
ホスホジエステラーゼ10阻害剤としてのアミノピリジンおよびカルボキシピリジン化合物
|
CA2748057C
(en)
|
2008-12-23 |
2018-07-03 |
Pharmasset, Inc. |
Nucleoside phosphoramidates
|
NZ593649A
(en)
*
|
2008-12-23 |
2013-11-29 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
TW201031675A
(en)
|
2008-12-23 |
2010-09-01 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
US20100159010A1
(en)
*
|
2008-12-24 |
2010-06-24 |
Mutual Pharmaceutical Company, Inc. |
Active Agent Formulations, Methods of Making, and Methods of Use
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
SG172784A1
(en)
|
2009-01-02 |
2011-08-29 |
Fournier Lab Ireland Ltd |
Novel use of fibrates
|
WO2010080754A2
(en)
|
2009-01-06 |
2010-07-15 |
Pharmanova, Inc. |
Nanoparticle pharmaceutical formulations
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
WO2010085641A1
(en)
|
2009-01-22 |
2010-07-29 |
Noramco, Inc. |
Process for preparing particles of opioids and compositions produced thereby
|
AR075180A1
(es)
*
|
2009-01-29 |
2011-03-16 |
Novartis Ag |
Formulaciones orales solidas de una pirido-pirimidinona
|
BRPI1007557A2
(pt)
|
2009-01-30 |
2016-02-16 |
Meiji Seika Pharma Co Ltd |
composição, e, processo para produzir uma composição
|
WO2010091164A1
(en)
|
2009-02-06 |
2010-08-12 |
Exelixis, Inc. |
Inhibitors of glucosylceramide synthase
|
WO2010091104A1
(en)
|
2009-02-06 |
2010-08-12 |
Exelixis, Inc. |
Glucosylceramide synthase inhibitors
|
CN104523661A
(zh)
|
2009-02-06 |
2015-04-22 |
南加利福尼亚大学 |
含有单萜的治疗组合物
|
US20100204265A1
(en)
*
|
2009-02-09 |
2010-08-12 |
Genelabs Technologies, Inc. |
Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
|
EP2398791A1
(de)
|
2009-02-18 |
2011-12-28 |
Amgen, Inc |
Indol/benzimidazolverbindungen als mtor-kinase-inhibitoren
|
DK2400950T3
(da)
|
2009-02-26 |
2019-07-29 |
Glaxo Group Ltd |
Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
|
US9060927B2
(en)
*
|
2009-03-03 |
2015-06-23 |
Biodel Inc. |
Insulin formulations for rapid uptake
|
US8538707B2
(en)
|
2009-03-11 |
2013-09-17 |
Mannkind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
JP5841044B2
(ja)
|
2009-03-23 |
2016-01-06 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
複合糖質ワクチン
|
US7828996B1
(en)
|
2009-03-27 |
2010-11-09 |
Abbott Cardiovascular Systems Inc. |
Method for the manufacture of stable, nano-sized particles
|
WO2010117662A1
(en)
|
2009-03-30 |
2010-10-14 |
Exelixis, Inc. |
Modulators of s1p and methods of making and using
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
MX2011010621A
(es)
*
|
2009-04-09 |
2012-01-30 |
Alkermes Pharma Ireland Ltd |
Composiciones de clozapina de liberacion controlada.
|
US20100268187A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Ranbaxy Laboratories Limited |
Packaging for sirolimus and composition thereof
|
JP6222924B2
(ja)
|
2009-04-24 |
2017-11-01 |
イシューティカ ピーティーワイ リミテッド |
ジクロフェナクの新規製剤
|
MY159208A
(en)
|
2009-04-24 |
2016-12-30 |
Iceutica Pty Ltd |
A novel formulation of indomethacin
|
US20100291221A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Robert Owen Cook |
Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
|
US10952965B2
(en)
*
|
2009-05-15 |
2021-03-23 |
Baxter International Inc. |
Compositions and methods for drug delivery
|
EP2253306A1
(de)
|
2009-05-18 |
2010-11-24 |
Royal College of Surgeons in Ireland |
Orodispersible Dosierungsformen mit Festarzneimitteldispersionen
|
GB2483815B
(en)
|
2009-05-18 |
2013-12-25 |
Sigmoid Pharma Ltd |
Composition comprising oil drops
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
WO2010135568A1
(en)
|
2009-05-22 |
2010-11-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of mtor and their use to treat cancer
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
JP6072539B2
(ja)
|
2009-05-27 |
2017-02-01 |
アルカーメス ファーマ アイルランド リミテッド |
ナノ粒子活性物質組成物におけるフレーク状凝集の軽減
|
FR2945950A1
(fr)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
Compositions de nanoparticules anticancereuses et procedes pour les preparer
|
TR200904500A2
(tr)
|
2009-06-10 |
2009-10-21 |
Öner Levent |
Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
|
EA025054B1
(ru)
|
2009-06-12 |
2016-11-30 |
Сайнэпсус Терапьютикс, Инк. |
Единичная дозированная форма для сублингвального введения, включающая частицы апоморфина, для лечения болезни паркинсона или половой дисфункции
|
KR101875969B1
(ko)
|
2009-06-12 |
2018-07-06 |
맨카인드 코포레이션 |
한정된 비표면적을 갖는 디케토피페라진 마이크로입자
|
HUE048542T2
(hu)
|
2009-06-16 |
2020-08-28 |
Pfizer |
Apixaban adagolási formái
|
WO2011005496A2
(en)
|
2009-06-22 |
2011-01-13 |
Massachusetts Eye & Ear Infirmary |
Islet1 (isl1) and hearing loss
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
US20110003000A1
(en)
*
|
2009-07-06 |
2011-01-06 |
Femmepharma Holding Company, Inc. |
Transvaginal Delivery of Drugs
|
EP2451442A4
(de)
|
2009-07-09 |
2014-02-12 |
Oshadi Drug Administration Ltd |
Matrixträgerzusammensetzungen, verfahren und verwendungen
|
WO2011006066A1
(en)
|
2009-07-10 |
2011-01-13 |
Ironwood Pharmaceuticals, Inc. |
Cb receptor agonists
|
EP2283824B1
(de)
|
2009-07-30 |
2017-04-19 |
Special Products Line S.p.A. |
Zusammensetzungen und Formulierungen, die auf quellbaren Matrizen basieren, zur verzögerten Freisetzung von schlecht löslichen Arzneimitteln, wie zum Beispiel Clarithromycin
|
AR077692A1
(es)
|
2009-08-06 |
2011-09-14 |
Vitae Pharmaceuticals Inc |
Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
BR112012002963A2
(pt)
|
2009-08-12 |
2017-10-24 |
Sigmoid Pharma Ltd |
composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa
|
EP2298296A1
(de)
|
2009-08-25 |
2011-03-23 |
CNRS Centre National De La Recherche Scientifique |
Zusammensetzung und Behandlung kognitiver Beeinträchtigungen bei Personen mit Down-Syndrom
|
ES2545794T3
(es)
|
2009-08-28 |
2015-09-15 |
Research Development Foundation |
Análogos de urocortina 2 y usos de los mismos
|
US9775819B2
(en)
*
|
2009-09-16 |
2017-10-03 |
R.P. Scherer Technologies, Llc |
Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
EP2488160B1
(de)
*
|
2009-10-16 |
2020-07-01 |
Lifecare Innovations Pvt. Ltd. |
Amphotericin-liposomenformulierung, umfassend cholesterin für die bekämpfung von pilzinfektionen
|
EP2490679B8
(de)
|
2009-10-22 |
2022-10-26 |
Tpc-Api Llc |
Verfahren zur herstellung und verwendung von zusammensetzungen mit flavonoiden
|
CA2778698A1
(en)
|
2009-11-03 |
2011-05-12 |
Mannkind Corporation |
An apparatus and method for simulating inhalation efforts
|
CA2779681A1
(en)
|
2009-11-05 |
2011-05-12 |
Lexicon Pharmaceuticals, Inc. |
Tryptophan hydroxylase inhibitors for the treatment of cancer
|
JP6310636B2
(ja)
*
|
2009-11-10 |
2018-04-11 |
セルジーン コーポレイション |
マイクロ流体化処理によって作製された難溶性薬物のナノ懸濁液
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
EP2586426B1
(de)
|
2009-12-03 |
2015-09-23 |
Alcon Research, Ltd. |
Carboxyvinylpolymer-haltige Nanopartikelsuspension
|
CN102762211A
(zh)
*
|
2009-12-09 |
2012-10-31 |
拜欧利纳斯有限公司 |
改善认知功能的方法
|
JP2013513605A
(ja)
|
2009-12-11 |
2013-04-22 |
エグゼリクシス, インコーポレイテッド |
Tgr5アゴニスト
|
TW201132353A
(en)
|
2009-12-18 |
2011-10-01 |
Amgen Inc |
WISE binding agents and epitopes
|
MX2012007234A
(es)
|
2009-12-22 |
2012-07-30 |
Leo Pharma As |
Nanocristales de monohidrato de calciprotiol.
|
UY33110A
(es)
|
2009-12-23 |
2011-07-29 |
Ironwood Pharmaceuticals Inc |
Moduladores de CRTH2
|
KR20120129927A
(ko)
|
2010-01-27 |
2012-11-28 |
글락소 그룹 리미티드 |
변형된 투베르쿨로시스 항원
|
US9028873B2
(en)
*
|
2010-02-08 |
2015-05-12 |
Southwest Research Institute |
Nanoparticles for drug delivery to the central nervous system
|
US20130196960A1
(en)
|
2010-02-09 |
2013-08-01 |
Ironwood Pharmaceuticals, Inc. |
Cannabinoid Receptor Agonists
|
US8901137B2
(en)
|
2010-02-09 |
2014-12-02 |
Exelixis, Inc. |
Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
|
US20130178453A1
(en)
|
2010-02-09 |
2013-07-11 |
Ironwood Pharmaceuticals, Inc. |
Cannabinoid Agonists
|
CA2789229A1
(en)
|
2010-02-10 |
2011-08-18 |
Lexicon Pharmaceuticals, Inc. |
Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
|
CA2789711C
(en)
|
2010-02-17 |
2014-08-05 |
Amgen Inc. |
Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
|
JP5770751B2
(ja)
|
2010-02-22 |
2015-08-26 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ピリド[3,2−d]ピリミジン系のPI3Kデルタ阻害化合物および使用方法
|
US8377929B2
(en)
*
|
2010-02-24 |
2013-02-19 |
Ramot At Tel-Aviv University Ltd. |
Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same
|
CN102791368B
(zh)
*
|
2010-03-11 |
2015-11-25 |
浜松光子学株式会社 |
微粒子分散液制造方法和微粒子分散液制造装置
|
AU2011230144B2
(en)
|
2010-03-22 |
2015-01-22 |
Bio-Synectics Inc. |
Method for preparing nano-particles
|
WO2011123672A1
(en)
|
2010-03-31 |
2011-10-06 |
Pharmasset, Inc. |
Purine nucleoside phosphoramidate
|
KR101715981B1
(ko)
|
2010-03-31 |
2017-03-13 |
길리애드 파마셋 엘엘씨 |
뉴클레오사이드 포스포르아미데이트
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
DE102010003711B4
(de)
*
|
2010-04-08 |
2015-04-09 |
Jesalis Pharma Gmbh |
Verfahren zur Herstellung kristalliner Wirkstoffpartikel
|
US20110269735A1
(en)
|
2010-04-19 |
2011-11-03 |
Celera Corporation |
Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
|
PL3486320T3
(pl)
|
2010-04-23 |
2022-05-09 |
University Of Florida Research Foundation, Inc. |
Kompozycje RAAV-cyklazy guanylanowej i sposoby leczenia wrodzonej amaurozy-1 Lebera (LCA1)
|
US9101541B2
(en)
|
2010-04-28 |
2015-08-11 |
Cadila Healthcare Limited |
Stable solid pharmaceutical matrix compositions of sirolimus
|
EP2566461A2
(de)
*
|
2010-05-05 |
2013-03-13 |
Ratiopharm GmbH |
Festes tapentadol in nicht-kristalliner form
|
US8362007B1
(en)
|
2010-05-11 |
2013-01-29 |
Demerx, Inc. |
Substituted noribogaine
|
US8765737B1
(en)
|
2010-05-11 |
2014-07-01 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
US9394294B2
(en)
|
2010-05-11 |
2016-07-19 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
AU2011253143A1
(en)
|
2010-05-13 |
2012-12-06 |
Amgen Inc. |
Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
|
CA2799020A1
(en)
|
2010-05-13 |
2011-11-17 |
Jennifer R. Allen |
Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
|
JP5702855B2
(ja)
|
2010-05-13 |
2015-04-15 |
アムジエン・インコーポレーテツド |
Pde10阻害剤として有用な窒素複素環化合物
|
WO2011143495A1
(en)
|
2010-05-13 |
2011-11-17 |
Amgen Inc. |
Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
|
HUE033315T2
(en)
|
2010-05-14 |
2017-11-28 |
Amgen Inc |
High concentration antibody preparations
|
US9012511B2
(en)
|
2010-05-19 |
2015-04-21 |
Alkermes Pharma Ireland Limited |
Nanoparticulate cinacalcet compositions
|
HUP1000325A2
(en)
|
2010-06-18 |
2012-01-30 |
Druggability Technologies Ip Holdco Jersey Ltd |
Nanostructured aprepitant compositions and process for their preparation
|
RU2571331C1
(ru)
|
2010-06-21 |
2015-12-20 |
Маннкайнд Корпорейшн |
Системы и способы доставки сухих порошковых лекарств
|
US8741891B1
(en)
|
2010-06-22 |
2014-06-03 |
Demerx, Inc. |
N-substituted noribogaine prodrugs
|
US9586954B2
(en)
|
2010-06-22 |
2017-03-07 |
Demerx, Inc. |
N-substituted noribogaine prodrugs
|
US8802832B2
(en)
|
2010-06-22 |
2014-08-12 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
US8637648B1
(en)
|
2010-06-22 |
2014-01-28 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
EP3263111A1
(de)
|
2010-06-30 |
2018-01-03 |
Victoria Link Ltd |
Verfahren und zusammensetzungen zur behandlung von multipler sklerose
|
CA2803900A1
(en)
|
2010-07-09 |
2012-01-12 |
Exelixis, Inc. |
Combinations of kinase inhibitors for the treatment of cancer
|
US20130259830A1
(en)
|
2010-07-12 |
2013-10-03 |
Ironwood Pharmaceuticals, Inc. |
Crth2 modulators
|
US20130216552A1
(en)
|
2010-07-12 |
2013-08-22 |
Ironwood Pharmaceuticals, Inc. |
Crth2 modulators
|
UA111065C2
(uk)
|
2010-07-23 |
2016-03-25 |
Демеркс, Інк. |
Композиції норибогаїну
|
US10449177B2
(en)
|
2010-08-19 |
2019-10-22 |
Buck Institute For Research On Aging |
Methods of treating mild cognitive impairment (MCI) and related disorders
|
ES2612503T3
(es)
|
2010-09-14 |
2017-05-17 |
Exelixis, Inc. |
Compuestos 9H-purina como inhibidores de PI3K-delta y métodos para su preparación
|
WO2012037132A1
(en)
|
2010-09-14 |
2012-03-22 |
Exelixis, Inc. |
Phtalazine derivatives as jak1 inhibitors
|
AR082985A1
(es)
|
2010-09-14 |
2013-01-23 |
Exelixis Inc |
INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
|
WO2012038963A1
(en)
|
2010-09-22 |
2012-03-29 |
Ramot At Tel-Aviv University Ltd. |
An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
|
EP2618828B1
(de)
|
2010-09-23 |
2016-11-23 |
Nuformix Limited |
Aprepitant-l-prolin-zusammensetzung und kokristall
|
UA114172C2
(uk)
|
2010-09-27 |
2017-05-10 |
Екселіксіс, Інк. |
Подвійні інгібітори мен і фрес для лікування кастраційно-резистентного раку простати та остеобластичних метастазів у кістці
|
CA2812744A1
(en)
|
2010-09-27 |
2012-04-05 |
Exelixis, Inc. |
Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
|
CN103391772A
(zh)
|
2010-09-27 |
2013-11-13 |
埃克塞里艾克西斯公司 |
用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
|
WO2012051426A2
(en)
*
|
2010-10-15 |
2012-04-19 |
Glaxo Group Limited |
Aggregate nanoparticulate medicament formulations, manufacture and use thereof
|
MX2013004981A
(es)
*
|
2010-11-02 |
2013-11-04 |
Univ Nebraska |
Composiciones y metodos para la administracion de agentes terapeuticos.
|
US20120108651A1
(en)
|
2010-11-02 |
2012-05-03 |
Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) |
Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
|
WO2012061337A1
(en)
|
2010-11-02 |
2012-05-10 |
Exelixis, Inc. |
Fgfr2 modulators
|
WO2012065019A2
(en)
|
2010-11-12 |
2012-05-18 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of p13k alpha
|
WO2012065057A2
(en)
|
2010-11-12 |
2012-05-18 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors and methods of their use
|
US20140080810A1
(en)
|
2010-11-15 |
2014-03-20 |
Exelixis, Inc. |
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
|
WO2012068106A2
(en)
|
2010-11-15 |
2012-05-24 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
WO2012071509A2
(en)
|
2010-11-24 |
2012-05-31 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
EP3042910B1
(de)
|
2010-11-30 |
2019-01-09 |
Gilead Pharmasset LLC |
2'-spiro-nukleoside zur therapie von hepatitis c
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
AU2011338389A1
(en)
|
2010-12-09 |
2013-06-13 |
Amgen Inc. |
Bicyclic compounds as Pim inhibitors
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
PL2651357T3
(pl)
|
2010-12-16 |
2020-08-24 |
Sunovion Pharmaceuticals Inc. |
Filmy podjęzykowe
|
EP2658857B1
(de)
|
2010-12-29 |
2016-11-02 |
Inhibitex, Inc. |
Substituierte purin-nukleoside, phosphoroamidate und phosphorodiamidatderivate zur behandlung von virusinfektionen
|
JP2014505052A
(ja)
|
2011-01-06 |
2014-02-27 |
ベータ ファルマ カナダ インコーポレーテッド |
癌の治療および予防用の新規なウレア
|
EP2481740B1
(de)
|
2011-01-26 |
2015-11-04 |
DemeRx, Inc. |
Verfahren und Zusammensetzungen zur Herstellung von Noribogain aus Voacangin
|
CN103649118A
(zh)
|
2011-03-01 |
2014-03-19 |
安进公司 |
双特异性结合剂
|
JP2014510105A
(ja)
|
2011-03-22 |
2014-04-24 |
アムジエン・インコーポレーテツド |
Pim阻害剤としてのアゾール化合物
|
CN103517920B
(zh)
|
2011-03-25 |
2018-04-17 |
安进公司 |
抗硬化蛋白(sclerostin)抗体晶体及其制剂
|
BR122020008875B8
(pt)
|
2011-04-01 |
2022-12-06 |
Mannkind Corp |
Embalagem de bolha e método de fabricação de uma embalagem de bolhas
|
RS60651B1
(sr)
|
2011-04-15 |
2020-09-30 |
Janssen Pharmaceutica Nv |
Nanosuspenzije leka osušene zamrzavanjem
|
EP3682896A1
(de)
|
2011-04-28 |
2020-07-22 |
University of Southern California |
Aus menschlichen myeloiden suppressorzellen gewonnene krebsmarker
|
AU2012249500A1
(en)
|
2011-04-29 |
2013-11-28 |
Exelixis, Inc. |
Method of treating lymphoma using pyridopyrimidinone inhibitors of PI3K/MTOR
|
MX2013012661A
(es)
|
2011-04-29 |
2014-03-27 |
Amgen Inc |
Compuestos de piridazina biciclicos como inhibidores pim.
|
US9221760B2
(en)
|
2011-05-09 |
2015-12-29 |
Van Andel Research Institute |
Autophagy inhibitors
|
JP2014521381A
(ja)
|
2011-05-13 |
2014-08-28 |
ブロンカス テクノロジーズ, インコーポレイテッド |
組織の切除のための方法およびデバイス
|
US8709034B2
(en)
|
2011-05-13 |
2014-04-29 |
Broncus Medical Inc. |
Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
|
EP2710005B1
(de)
|
2011-05-17 |
2016-10-05 |
Principia Biopharma Inc. |
Tyrosinkinase-hemmer
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
US20140107151A1
(en)
|
2011-05-17 |
2014-04-17 |
Principia Biophama Inc. |
Tyrosine kinase inhibitors
|
CA2836417A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Azaindole derivatives as tyrosine kinase inhibitors
|
PT3415139T
(pt)
|
2011-06-14 |
2022-06-20 |
Neurelis Inc |
Administração de benzodiazepina
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
CN103608030A
(zh)
|
2011-06-21 |
2014-02-26 |
昂科发克特公司 |
用于治疗和诊断癌症的组合物和方法
|
JP5978296B2
(ja)
|
2011-06-28 |
2016-08-24 |
フジアン・ミンドン・レジュヴネイション・ファーマスーティカル・カンパニー・リミテッド |
抗アレルギ性ベンゾシクロヘプタチオフェン誘導体
|
ES2624984T3
(es)
|
2011-07-15 |
2017-07-18 |
Viiv Healthcare Uk Limited |
Derivados de ácido 2-(pirrolo[2,3-b]piridin-5-il)-2-(t-butoxi)-acético como inhibidores de la replicación del VIH para el tratamiento del SIDA
|
MX2014000658A
(es)
|
2011-07-22 |
2014-07-09 |
Chemocentryx Inc |
Formas poliformicas de la sal de sodio de 4-ter-butil-n-[4 -cloro-2-(1-oxi-piridina-4-carbonil)-fenil]-bencensulfonamida.
|
RS56023B1
(sr)
|
2011-07-22 |
2017-09-29 |
Chemocentryx Inc |
Kristalni oblik natrijumove soli 4-terc-butil-n-[4-hlor-2-(1-okso-piridin-4-karbonil)-fenil]-benzensulfonamida
|
DK2739311T3
(en)
|
2011-08-04 |
2018-04-23 |
Amgen Inc |
Method of treating bone slit defects
|
US9617274B1
(en)
|
2011-08-26 |
2017-04-11 |
Demerx, Inc. |
Synthetic noribogaine
|
PL2751094T3
(pl)
|
2011-09-01 |
2018-11-30 |
Glaxo Group Limited |
Nowa postać krystaliczna
|
TW201325592A
(zh)
|
2011-09-14 |
2013-07-01 |
Exelixis Inc |
用於治療癌症之磷脂醯肌醇-3激酶抑制劑
|
KR101794032B1
(ko)
|
2011-09-21 |
2017-11-07 |
(주)바이오시네틱스 |
나노입자 제조방법
|
ES2632443T3
(es)
|
2011-09-22 |
2017-09-13 |
Viiv Healthcare Uk Limited |
Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH
|
AU2012312364B2
(en)
|
2011-09-22 |
2017-11-09 |
Exelixis, Inc. |
Method for treating osteoporosis
|
CA2850187C
(en)
|
2011-09-29 |
2021-12-07 |
Plx Pharma Inc. |
Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
|
WO2013056067A1
(en)
|
2011-10-13 |
2013-04-18 |
Exelixis, Inc. |
Compounds for use in the treatment of basal cell carcinoma
|
TWI580442B
(zh)
*
|
2011-10-19 |
2017-05-01 |
傑特大學 |
醫藥毫微懸浮物
|
CA2852536A1
(en)
|
2011-10-24 |
2013-05-02 |
Mannkind Corporation |
Methods and compositions for treating pain
|
CN104302294A
(zh)
|
2011-11-01 |
2015-01-21 |
埃克塞利希斯股份有限公司 |
用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3-激酶抑制剂的n-(3-{[(3-{[2-氯-5-(甲氧基)苯基]氨基}喹喔啉-2-基)氨基]磺酰基}苯基)-2-甲基丙氨酰胺
|
WO2013067306A1
(en)
|
2011-11-02 |
2013-05-10 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
|
CN104159585A
(zh)
|
2011-11-08 |
2014-11-19 |
埃克塞里艾克西斯公司 |
用于治疗癌症的met和vegf双重抑制剂
|
CN104039226A
(zh)
|
2011-11-08 |
2014-09-10 |
埃克塞里艾克西斯公司 |
定量癌症治疗的方法
|
CA2855358C
(en)
|
2011-11-11 |
2021-03-16 |
Fred Hutchinson Cancer Research Center |
Cyclin a1-targeted t-cell immunotherapy for cancer
|
EP2780009A4
(de)
|
2011-11-17 |
2015-05-06 |
Univ Colorado Regents |
Verfahren und zusammensetzungen zur verbesserten wirkstofffreisetzung ins auge und formulierungen mit verlängerter freisetzung
|
WO2013078235A1
(en)
|
2011-11-23 |
2013-05-30 |
Broncus Medical Inc |
Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
|
US9532993B2
(en)
|
2011-11-25 |
2017-01-03 |
Nuformix Limited |
Aprepitant L-proline solvates—compositions and cocrystals
|
EP2788003A4
(de)
|
2011-12-09 |
2015-05-27 |
Demerx Inc |
Phosphatester von noribogain
|
JO3387B1
(ar)
|
2011-12-16 |
2019-03-13 |
Glaxosmithkline Llc |
مشتقات بيتولين
|
ES2813524T3
(es)
|
2011-12-28 |
2021-03-24 |
Amgen Inc |
Método para tratar la pérdida de hueso alveolar mediante el uso de anticuerpos antiesclerostina
|
US9150584B2
(en)
|
2012-01-25 |
2015-10-06 |
Demerx, Inc. |
Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
|
CA2858820C
(en)
|
2012-01-25 |
2021-08-17 |
Demerx, Inc. |
Synthetic voacangine
|
CN104203272A
(zh)
|
2012-01-26 |
2014-12-10 |
长角牛疫苗和诊断有限责任公司 |
复合抗原序列及疫苗
|
TW201348226A
(zh)
|
2012-02-28 |
2013-12-01 |
Amgen Inc |
作為pim抑制劑之醯胺
|
TW201348231A
(zh)
|
2012-02-29 |
2013-12-01 |
Amgen Inc |
雜雙環化合物
|
KR102236462B1
(ko)
|
2012-03-19 |
2021-04-08 |
시다라 세라퓨틱스, 인코포레이티드 |
에키노칸딘 계열의 화합물에 대한 투여 용법
|
CA2867701C
(en)
|
2012-03-22 |
2020-10-27 |
Nanotherapeutics, Inc. |
Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
|
KR101956586B1
(ko)
*
|
2012-03-27 |
2019-03-11 |
일양약품주식회사 |
약제학적 조성물 및 이의 제조방법
|
US20130303763A1
(en)
|
2012-03-30 |
2013-11-14 |
Michael D. Gershon |
Methods and compositions for the treatment of necrotizing enterocolitis
|
US20150080381A1
(en)
|
2012-04-12 |
2015-03-19 |
Ironwood Pharmaceuticals, Inc. |
Methods of treating alopecia and acne
|
US9452107B2
(en)
|
2012-04-16 |
2016-09-27 |
New Jersey Institute Of Technology |
Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
|
US9861624B2
(en)
|
2012-05-02 |
2018-01-09 |
Exelixis, Inc. |
Method of treating cancer
|
KR102140989B1
(ko)
|
2012-05-03 |
2020-08-04 |
칼라 파마슈티컬스, 인크. |
개선된 점막 수송을 나타내는 제약 나노입자
|
WO2013166408A1
(en)
|
2012-05-03 |
2013-11-07 |
Kala Pharmaceuticals, Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
US9827191B2
(en)
|
2012-05-03 |
2017-11-28 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
US11596599B2
(en)
|
2012-05-03 |
2023-03-07 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
ES2952419T3
(es)
|
2012-05-11 |
2023-10-31 |
Activus Pharma Co Ltd |
Nanopolvo de compuesto orgánico, método de producción del mismo, y suspensión
|
JP6234443B2
(ja)
|
2012-05-17 |
2017-11-22 |
ブイティーブイ・セラピューティクス・エルエルシー |
糖尿病治療のためのグルコキナーゼ活性化因子組成物
|
UA126959C2
(uk)
|
2012-06-04 |
2023-03-01 |
Фармасайклікс Ллс |
Фармацевтична композиція, що містить інгібітор тирозинкінази брутона
|
AR091436A1
(es)
|
2012-06-14 |
2015-02-04 |
Amgen Inc |
Compuestos de azetidina y piperidina utiles como inhibidores de pde10
|
EP3597178A1
(de)
|
2012-06-21 |
2020-01-22 |
Phosphorex Inc. |
Nanopartikel aus indirubin, derivate davon sowie verfahren zur herstellung und verwendung davon
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
CN104619342A
(zh)
|
2012-07-05 |
2015-05-13 |
Ucb医药有限公司 |
骨疾病的治疗
|
ES2647437T3
(es)
|
2012-07-12 |
2017-12-21 |
Viiv Healthcare Uk Limited |
Compuestos y procedimientos para tratar el VIH
|
KR102264177B1
(ko)
|
2012-07-12 |
2021-06-11 |
맨카인드 코포레이션 |
건조 분말 약물 전달 시스템 및 방법
|
JOP20130213B1
(ar)
|
2012-07-17 |
2021-08-17 |
Takeda Pharmaceuticals Co |
معارضات لمستقبلht3-5
|
WO2014022752A1
(en)
|
2012-08-03 |
2014-02-06 |
Amgen Inc. |
Macrocycles as pim inhibitors
|
EP2882722B1
(de)
|
2012-08-13 |
2016-07-27 |
Takeda Pharmaceutical Company Limited |
Chinoxalinderivate als gpr6-modulatoren
|
CA2882713A1
(en)
|
2012-08-22 |
2014-02-27 |
Xenoport, Inc. |
Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
|
EP2887935A1
(de)
|
2012-08-22 |
2015-07-01 |
XenoPort, Inc. |
Orale dosierformen von methylwasserstofffumarat und prodrugs davon
|
WO2014031178A1
(en)
|
2012-08-24 |
2014-02-27 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
EP2890691B1
(de)
|
2012-08-31 |
2018-04-25 |
Principia Biopharma Inc. |
Benzimidazolderivate als itk-inhibitoren
|
CA2922849A1
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
NZ630925A
(en)
|
2012-09-10 |
2016-10-28 |
Principia Biopharma Inc |
Pyrazolopyrimidine compounds as kinase inhibitors
|
US10159644B2
(en)
|
2012-10-26 |
2018-12-25 |
Mannkind Corporation |
Inhalable vaccine compositions and methods
|
WO2014081732A1
(en)
|
2012-11-20 |
2014-05-30 |
Principia Biopharma Inc. |
Azaindole derivatives as jak3 inhibitors
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
CA2896577C
(en)
|
2012-11-30 |
2024-01-23 |
Sanford-Burnham Medical Research Institute |
Inhibitor of apoptosis protein (iap) antagonists
|
WO2014091318A1
(en)
|
2012-12-11 |
2014-06-19 |
Lupin Atlantis Holdings, S.A. |
Reduced dose pharmaceutical compositions of fenofibrate
|
WO2014100021A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
|
JP2016508979A
(ja)
|
2012-12-20 |
2016-03-24 |
デメレックス, インコーポレイテッド |
置換ノルイボガイン
|
US8940728B2
(en)
|
2012-12-20 |
2015-01-27 |
Demerx, Inc. |
Substituted noribogaine
|
US9045481B2
(en)
|
2012-12-20 |
2015-06-02 |
Demerx, Inc. |
Substituted noribogaine
|
EP2951205B1
(de)
|
2013-02-01 |
2021-08-11 |
Santa Maria Biotherapeutics, Inc. |
Anti-aktivin-a-verbindungen zur behandlung vom ovarialkrebs
|
WO2014134415A1
(en)
*
|
2013-02-28 |
2014-09-04 |
Sun Chemical Corporation |
Continuous contained-media micromedia milling process
|
KR20150123838A
(ko)
*
|
2013-03-04 |
2015-11-04 |
브이티브이 테라퓨틱스 엘엘씨 |
안정한 글루코키나제 활성화제 조성물
|
WO2014160177A2
(en)
|
2013-03-13 |
2014-10-02 |
Exelixis, Inc. |
Quinazoline inhibitors of pi3k
|
BR112015023168B1
(pt)
|
2013-03-15 |
2021-08-10 |
Mannkind Corporation |
Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
|
JP2016512226A
(ja)
|
2013-03-15 |
2016-04-25 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
緩衝化アミノアルキルグルコサミニドホスフェート誘導体を含有する組成物及び免疫応答を増強するためのその使用
|
US9732068B1
(en)
|
2013-03-15 |
2017-08-15 |
GenSyn Technologies, Inc. |
System for crystalizing chemical compounds and methodologies for utilizing the same
|
US10179118B2
(en)
|
2013-03-24 |
2019-01-15 |
Arbor Pharmaceuticals, Llc |
Pharmaceutical compositions of dimethyl fumarate
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
PT2981271T
(pt)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Utilizações terapêuticas de empagliflozina
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
PL2986304T3
(pl)
|
2013-04-18 |
2022-05-02 |
Boehringer Ingelheim International Gmbh |
Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
|
EP2994470B1
(de)
|
2013-05-09 |
2018-04-18 |
Principia Biopharma Inc. |
Pyrido[2,3-d]pyrimidin-derivate als inhibitoren des fibroblastenwachstumsfaktors
|
WO2014197860A1
(en)
|
2013-06-07 |
2014-12-11 |
Xenoport, Inc. |
Method of making monomethyl fumarate
|
AU2014282762B2
(en)
|
2013-06-20 |
2016-11-10 |
Ichnos Sciences SA |
Nanoparticulate formulation comprising a TRPA1 antagonist
|
US9421182B2
(en)
|
2013-06-21 |
2016-08-23 |
Xenoport, Inc. |
Cocrystals of dimethyl fumarate
|
CN114848614A
(zh)
|
2013-07-18 |
2022-08-05 |
曼金德公司 |
热稳定性干粉药物组合物和方法
|
EP3030294B1
(de)
|
2013-08-05 |
2020-10-07 |
MannKind Corporation |
Insufflationsvorrichtung
|
US9416096B2
(en)
|
2013-09-06 |
2016-08-16 |
Xenoport, Inc. |
Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
|
US20150079180A1
(en)
|
2013-09-18 |
2015-03-19 |
Xenoport, Inc. |
Nanoparticle compositions of dimethyl fumarate
|
GB201319791D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
WO2015071841A1
(en)
|
2013-11-12 |
2015-05-21 |
Druggability Technologies Holdings Limited |
Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
|
EP2878311A1
(de)
|
2013-11-27 |
2015-06-03 |
Freund Pharmatec Ltd. |
Verbesserung der Löslichkeit für hydrophobe Wirkstoffe
|
JP6510539B2
(ja)
|
2014-01-09 |
2019-05-08 |
ザ ジェイ. デヴィッド グラッドストーン インスティテューツ, ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ. デヴィッド グラッドストーン |
置換ベンゾオキサジン及び関連化合物
|
WO2015108945A2
(en)
|
2014-01-14 |
2015-07-23 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the delivery of therapeutics
|
WO2015108783A1
(en)
|
2014-01-16 |
2015-07-23 |
The Brigham And Women's Hospital, Inc. |
Targeted delivery of immunoregulatory drugs
|
BR112016018948B1
(pt)
|
2014-02-21 |
2023-01-17 |
Principia Biopharma Inc |
Uso de composto ou sal farmaceuticamente aceitável, ácido sulfônico ou sal de ácido carboxílico de composto, forma amorfa de sal farmaceuticamente aceitável de composto, composição farmacêutica e respectivo uso
|
WO2015134210A1
(en)
|
2014-03-03 |
2015-09-11 |
Principia Biopharma, Inc. |
BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
|
WO2015134608A1
(en)
|
2014-03-05 |
2015-09-11 |
Nanotherapeutics, Inc. |
Compositions and methods for oral delivery of encapsulated 3-aminopyridine-2-carboxaldehyde particles
|
US9999672B2
(en)
|
2014-03-24 |
2018-06-19 |
Xenoport, Inc. |
Pharmaceutical compositions of fumaric acid esters
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
PT3134084T
(pt)
|
2014-04-25 |
2021-05-11 |
Exelixis Inc |
Método de tratamento de adenocarcinoma do pulmão
|
CN107072976A
(zh)
|
2014-05-12 |
2017-08-18 |
葛兰素史克知识产权第二有限公司 |
用于治疗传染性疾病的包含Danirixin的药物组合物
|
US9526734B2
(en)
|
2014-06-09 |
2016-12-27 |
Iceutica Pty Ltd. |
Formulation of meloxicam
|
CA2989550C
(en)
|
2014-06-18 |
2023-08-08 |
Demerx, Inc. |
Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
|
US10654843B2
(en)
|
2014-06-20 |
2020-05-19 |
Principia Biopharma Inc. |
LMP7 inhibitors
|
EA032017B1
(ru)
|
2014-06-25 |
2019-03-29 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Кристаллические соли (s)-6-((1-ацетилпиперидин-4-ил)амино)-n-(3-(3,4-дигидроизохинолин-2(1h)-ил)-2-гидроксипропил)пиримидин-4-карбоксамида
|
DK3174535T3
(da)
|
2014-08-01 |
2019-05-13 |
Glenmark Pharmaceuticals Sa |
Nanopartikelformulering, der omfatter en mpges-1-hæmmer
|
EP3182958B2
(de)
*
|
2014-08-18 |
2022-05-18 |
Alkermes Pharma Ireland Limited |
Aripiprazol-prodrugzusammensetzung
|
US10016415B2
(en)
*
|
2014-08-18 |
2018-07-10 |
Alkermes Pharma Ireland Limited |
Aripiprazole prodrug compositions
|
WO2016033556A1
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
|
US20170246187A1
(en)
|
2014-08-28 |
2017-08-31 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
US10987308B2
(en)
|
2014-09-03 |
2021-04-27 |
Genesegues, Inc. |
Therapeutic nanoparticles and related compositions, methods and systems
|
BR112017004673A2
(pt)
|
2014-09-08 |
2017-12-05 |
Glaxosmithkline Ip Dev Ltd |
formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
|
PL3201203T3
(pl)
|
2014-09-29 |
2021-11-22 |
Takeda Pharmaceutical Company Limited |
Krystaliczna postać 1-(1-metylo-1h-pirazol-4-ilo)-n-((1r,5s,7s)-9-metylo-3-oksa-9-azabicyklo[3.3.1]nonan-7-ylo)-1h-indolo-3-karboksyamidu
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
EP3203995A4
(de)
|
2014-10-09 |
2019-05-15 |
Board of Regents of the University of Nebraska |
Zusammensetzungen und verfahren zur abgabe von therapiemitteln
|
PL3215127T3
(pl)
|
2014-11-07 |
2021-05-17 |
Sublimity Therapeutics Limited |
Kompozycje zawierające cyklosporynę
|
ES2890662T3
(es)
*
|
2014-11-25 |
2022-01-21 |
Curadigm Sas |
Composiciones farmacéuticas, preparación y usos de las mismas
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
KR20170102002A
(ko)
|
2015-01-09 |
2017-09-06 |
이투빅스 코포레이션 |
에볼라 바이러스 백신접종을 위한 방법 및 조성물
|
CN104587457B
(zh)
*
|
2015-01-13 |
2017-03-22 |
广东海大畜牧兽医研究院有限公司 |
一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
|
US10166197B2
(en)
|
2015-02-13 |
2019-01-01 |
St. John's University |
Sugar ester nanoparticle stabilizers
|
EP3258918A1
(de)
|
2015-02-20 |
2017-12-27 |
Cytec Industries Inc. |
Dialkyl-sulfosuccinat-zusammensetzungen, verfahren zur herstellung und verfahren zur verwendung
|
AU2016226279B2
(en)
|
2015-03-03 |
2021-11-11 |
Pharmacyclics Llc |
Pharmaceutical formulations of Bruton's tyrosine kinase inhibtor
|
CA2980730A1
(en)
|
2015-03-23 |
2016-09-29 |
The Brigham And Women's Hospital, Inc. |
Tolerogenic nanoparticles for treating diabetes mellitus
|
CA3127926A1
(en)
|
2015-04-21 |
2016-10-27 |
Sunovion Pharmaceuticals Inc. |
Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
|
US9976136B2
(en)
|
2015-05-14 |
2018-05-22 |
Longhorn Vaccines And Diagnostics, Llc |
Rapid methods for the extraction of nucleic acids from biological samples
|
EP3298011B1
(de)
|
2015-05-22 |
2021-11-17 |
Principia Biopharma Inc. |
Chinolonderivate als fibroblasten-wachstumsfaktorrezeptorinhibitoren
|
WO2016196840A1
(en)
|
2015-06-03 |
2016-12-08 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
WO2016210165A1
(en)
|
2015-06-24 |
2016-12-29 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
WO2017004610A1
(en)
|
2015-07-02 |
2017-01-05 |
Exelixis, Inc. |
Tercyclic s1p3-sparing, s1p1 receptor agonists
|
WO2017004609A1
(en)
|
2015-07-02 |
2017-01-05 |
Exelixis, Inc. |
Thiadiazole modulators of s1p and methods of making and using
|
EP3317287B1
(de)
|
2015-07-02 |
2019-07-31 |
GlaxoSmithKline Intellectual Property Development Limited |
Inhibitoren der indoleamin-2,3-dioxygenase
|
WO2017004608A1
(en)
|
2015-07-02 |
2017-01-05 |
Exelixis, Inc. |
Oxadiazole modulators of s1p methods of making and using
|
CN108026139A
(zh)
|
2015-07-28 |
2018-05-11 |
葛兰素史克知识产权第二有限公司 |
用于预防或治疗hiv感染的白桦脂醇衍生物
|
CA2993753A1
(en)
|
2015-07-28 |
2017-02-02 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Betuin derivatives for preventing or treating hiv infections
|
JP2018536625A
(ja)
|
2015-09-24 |
2018-12-13 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
インドールアミン2,3−ジオキシゲナーゼのモジュレーター
|
CA2998828A1
(en)
|
2015-09-24 |
2017-03-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Compounds with hiv maturation inhibitory activity
|
JP6775010B2
(ja)
|
2015-09-24 |
2020-10-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
インドールアミン2,3−ジオキシゲナーゼのモジュレーター
|
EA036155B1
(ru)
|
2015-10-16 |
2020-10-06 |
Маринус Фармасьютикалс, Инк. |
Инъекционные составы нейростероида, содержащие наночастицы
|
WO2017130156A1
(en)
|
2016-01-27 |
2017-08-03 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Ingenol analogs, pharmaceutical compositions and methods of use thereof
|
US10159671B2
(en)
|
2016-02-17 |
2018-12-25 |
Alkermes Pharma Ireland Limited |
Compositions of multiple aripiprazole prodrugs
|
ES2883450T3
(es)
|
2016-02-17 |
2021-12-07 |
Global Blood Therapeutics Inc |
Inhibidores de histona metiltransferasa
|
EP3426674A4
(de)
|
2016-03-09 |
2019-08-14 |
Blade Therapeutics, Inc. |
Cyclische keto-amid-verbindungen als calpain-modulatoren sowie verfahren zur herstellung und verwendung davon
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
US10682340B2
(en)
|
2016-06-30 |
2020-06-16 |
Durect Corporation |
Depot formulations
|
JP7051721B2
(ja)
|
2016-06-30 |
2022-04-11 |
デュレクト コーポレーション |
デポー製剤
|
US20190328900A1
(en)
|
2016-07-01 |
2019-10-31 |
Glaxosmithkline Intellectual Property Development Limited |
Antibody-drug conjugates and therapeutic methods using the same
|
US11292801B2
(en)
|
2016-07-05 |
2022-04-05 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
US20180042903A1
(en)
|
2016-08-11 |
2018-02-15 |
Ovid Therapeutics Inc. |
Methods and compositions for treatment of epileptic disorders
|
WO2018033792A2
(en)
|
2016-08-19 |
2018-02-22 |
Orasis Pharmaceuticals Ltd. |
Ophthalmic pharmaceutical compositions and uses relating thereto
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
JP7086942B2
(ja)
|
2016-09-12 |
2022-06-20 |
インテグラル ヘルス, インコーポレイテッド |
Gpr120モジュレーターとして有用な単環式化合物
|
CA3036474A1
(en)
|
2016-09-13 |
2018-03-22 |
Kyowa Hakko Kirin Co., Ltd. |
Therapeutic agent for an ophthalmic disease comprising a vegf receptor inhibitor
|
JP2020500207A
(ja)
|
2016-09-28 |
2020-01-09 |
ブレード・セラピューティクス・インコーポレイテッド |
カルパインモジュレーター及びそれらの治療上の使用
|
US11160743B2
(en)
|
2016-10-11 |
2021-11-02 |
Dsm Ip Assets B.V. |
Preparation of nano-sized UV absorbers
|
JP2020503269A
(ja)
|
2016-11-28 |
2020-01-30 |
リポカイン インコーポレーテッド |
経口ウンデカン酸テストステロン療法
|
KR102544935B1
(ko)
|
2016-12-16 |
2023-06-21 |
코퍼스 퍼포먼스 케미컬스 인크. |
목재 방부제 및 그의 제조 방법
|
EP3558971B1
(de)
|
2016-12-22 |
2022-02-23 |
Global Blood Therapeutics, Inc. |
Histonmethyltransferaseaseinhibitoren
|
PL3571208T3
(pl)
|
2017-01-18 |
2021-09-20 |
Principia Biopharma Inc. |
Inhibitory immunoproteasomu
|
MX2019012176A
(es)
|
2017-04-10 |
2020-02-19 |
Sierra Oncology Inc |
Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
|
EP3609867A4
(de)
|
2017-04-11 |
2020-11-25 |
Saje Pharma, LLC |
Carbazolverbindungen und verfahren zur verwendung davon
|
BR112018072382A2
(pt)
|
2017-04-21 |
2019-02-12 |
Bio-Synectics Inc. |
método para preparar nanopartícula de ingrediente ativo
|
CN110997671A
(zh)
|
2017-06-09 |
2020-04-10 |
全球血液疗法股份有限公司 |
作为组蛋白甲基转移酶抑制剂的氮杂吲哚化合物
|
KR20200028964A
(ko)
|
2017-07-14 |
2020-03-17 |
얀센 파마슈티카 엔.브이. |
장기 작용 제형
|
WO2019036384A1
(en)
|
2017-08-15 |
2019-02-21 |
Global Blood Therapeutics, Inc. |
TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
|
WO2019036377A1
(en)
|
2017-08-15 |
2019-02-21 |
Global Blood Therapeutics, Inc. |
TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
|
WO2019087016A1
(en)
|
2017-10-30 |
2019-05-09 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds useful in hiv therapy
|
EP3710458A1
(de)
|
2017-11-16 |
2020-09-23 |
Principia Biopharma Inc. |
Immunproteasominhibitoren
|
HUE060020T2
(hu)
|
2017-11-16 |
2023-01-28 |
Principia Biopharma Inc |
Immunproteaszóma-gátlók
|
CA3126348A1
(en)
|
2018-01-12 |
2020-07-18 |
Board Of Regents Of The University Of Nebraska |
Antiviral prodrugs and formulations thereof
|
DE102018103528A1
(de)
|
2018-02-16 |
2019-08-22 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Suspension nanoskaliger, organischer Partikel und Verfahren zu ihrer Herstellung
|
WO2019169017A1
(en)
|
2018-02-28 |
2019-09-06 |
Bioxiness Pharmaceuticals, Inc. |
Chemotherapeutic agents
|
WO2019169029A1
(en)
|
2018-02-28 |
2019-09-06 |
Bioxiness Pharmaceuticals, Inc. |
Target specific chemotherapeutic agents
|
WO2019171174A2
(en)
*
|
2018-03-07 |
2019-09-12 |
St Ip Holding Ag |
Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
|
EP3762396A1
(de)
|
2018-03-07 |
2021-01-13 |
GlaxoSmithKline Intellectual Property (No.2) Limited |
Verbindungen zur verwendung in der hiv-therapie
|
EP3774879A1
(de)
|
2018-03-30 |
2021-02-17 |
Amgen Inc. |
C-terminale antikörpervarianten
|
US11458136B2
(en)
|
2018-04-09 |
2022-10-04 |
Board Of Regents Of The University Of Nebraska |
Antiviral prodrugs and formulations thereof
|
JPWO2019240104A1
(ja)
|
2018-06-11 |
2021-06-24 |
大塚製薬株式会社 |
デラマニド含有組成物
|
AU2019287437A1
(en)
|
2018-06-12 |
2020-09-10 |
Vtv Therapeutics Llc |
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
|
JP2021534112A
(ja)
|
2018-08-09 |
2021-12-09 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
Hiv療法に有用な化合物
|
JP2021536444A
(ja)
|
2018-08-30 |
2021-12-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
Hiv療法に有用な化合物
|
WO2020121006A2
(en)
|
2018-10-19 |
2020-06-18 |
Innostudio Inc. |
Method and apparatus to produce nanoparticles in an ostwald ripening flow device with tubes of variable path length
|
IL283487B1
(en)
|
2018-11-30 |
2024-03-01 |
Glaxosmithkline Ip Dev Ltd |
Compounds useful in curing HIV
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
MA54940A
(fr)
|
2019-01-22 |
2021-12-22 |
The Roskamp Inst |
Dérivés d'acides aminés pour le traitement de maladies inflammatoires
|
AU2020221821A1
(en)
|
2019-02-13 |
2021-08-26 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
JP2022525013A
(ja)
|
2019-03-06 |
2022-05-11 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッド |
Hiv療法において有用な化合物
|
CA3136443A1
(en)
|
2019-04-12 |
2020-10-15 |
Riboscience Llc |
Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
|
MX2022001553A
(es)
|
2019-08-05 |
2022-04-18 |
Marinus Pharmaceuticals Inc |
Ganaxolona para su uso en el tratamiento del estado epileptico.
|
WO2021024114A1
(en)
|
2019-08-08 |
2021-02-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
|
US20220298160A1
(en)
|
2019-08-28 |
2022-09-22 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Compounds useful in hiv therapy
|
MX2022006014A
(es)
|
2019-12-06 |
2022-06-22 |
Marinus Pharmaceuticals Inc |
Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
|
US20210244720A1
(en)
|
2020-01-20 |
2021-08-12 |
Genzyme Corporation |
Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)
|
KR20220158031A
(ko)
|
2020-03-26 |
2022-11-29 |
피엘엑스 옵코 인코포레이티드 |
pH 의존성 재구성이 가능한 제약 담체 및 그의 제조 및 사용 방법
|
AU2021257451A1
(en)
|
2020-04-17 |
2022-12-15 |
Genzyme Corporation |
Eclitasertib for use in treating conditions involving systemic hyperinflammatory response
|
CN115443136A
(zh)
|
2020-04-22 |
2022-12-06 |
普林斯匹亚生物制药公司 |
使用btk抑制剂对急性呼吸窘迫综合征和涉及细胞因子风暴的其他障碍的治疗
|
EP3928772A1
(de)
|
2020-06-26 |
2021-12-29 |
Algiax Pharmaceuticals GmbH |
Nanopartikuläre zusammensetzung
|
AU2021303490A1
(en)
|
2020-07-09 |
2023-03-09 |
Janssen Pharmaceutica Nv |
Long-acting formulations
|
JP2023532981A
(ja)
|
2020-07-09 |
2023-08-01 |
ヤンセン ファーマシューティカ エヌ.ベー. |
長時間作用型配合物
|
EP4178541A1
(de)
|
2020-07-09 |
2023-05-17 |
JANSSEN Pharmaceutica NV |
Formulierungen mit langzeitwirkung
|
CN112451520B
(zh)
*
|
2020-12-31 |
2021-10-15 |
江苏宇锐医药科技有限公司 |
一种缬沙坦氨氯地平组合物及其制备方法
|
EP4298105A1
(de)
|
2021-02-23 |
2024-01-03 |
VIIV Healthcare Company |
Verbindungen zur hiv-behandlung
|
WO2023023473A1
(en)
|
2021-08-16 |
2023-02-23 |
Sierra Oncology, Inc. |
Methods of using momelotinib to treat chronic kidney disease
|
WO2023034743A1
(en)
*
|
2021-08-31 |
2023-03-09 |
Natsar Pharmaceuticals, Inc. |
Intravenous formulations of rk-33
|
WO2023239727A1
(en)
|
2022-06-06 |
2023-12-14 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Lats inhibitors and uses thereof
|
WO2023244672A1
(en)
|
2022-06-14 |
2023-12-21 |
Assembly Biosciences, Inc. |
2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
|
WO2024006406A1
(en)
|
2022-06-30 |
2024-01-04 |
Genzyme Corporation |
Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis
|
WO2024010782A1
(en)
|
2022-07-06 |
2024-01-11 |
Vividion Therapeutics, Inc. |
Pharmaceutical compositions comprising wrn helicase inhibitors
|
WO2024010784A1
(en)
|
2022-07-06 |
2024-01-11 |
Vividion Therapeutics, Inc. |
Pharmaceutical compositions comprising wrn helicase inhibitors
|
WO2024068693A1
(en)
|
2022-09-28 |
2024-04-04 |
Janssen Pharmaceutica Nv |
Long-acting formulations
|
WO2024068699A1
(en)
|
2022-09-28 |
2024-04-04 |
Janssen Pharmaceutica Nv |
Long-acting formulations
|
CN115844821A
(zh)
*
|
2023-01-03 |
2023-03-28 |
江苏知原药业股份有限公司 |
一种地奈德纳米晶混悬液、制备方法及其应用
|